Fact-checked by Grok 2 weeks ago

Blood transfusion

A blood transfusion is a medical procedure in which whole blood or specific blood components, such as packed red blood cells, platelets, or plasma, are transferred from a donor to a recipient via an intravenous line to restore blood volume, enhance oxygen transport, or supply clotting factors.^[1] This intervention addresses acute conditions including hemorrhage from trauma or surgery, severe anemia, and hypovolemic shock, where empirical evidence demonstrates improved survival rates when hemoglobin levels fall below critical thresholds.^[2]^[3] Transfusions utilize fractionated components rather than whole blood to minimize risks like volume overload, with packed red blood cells providing oxygen-carrying capacity, platelets aiding hemostasis in thrombocytopenia, and fresh frozen plasma supplying coagulation factors for deficiencies.^[1] Compatibility testing based on ABO and Rh blood group systems, discovered in 1901, prevents acute hemolytic reactions by matching donor and recipient antigens.^[4] The procedure's efficacy stems from causal mechanisms where transfused erythrocytes directly augment tissue oxygenation, as validated in clinical trials for perioperative and critical care settings.^[1] Key historical milestones include the first successful human-to-human transfusion in 1818 by James Blundell for postpartum hemorrhage and the development of anticoagulants like citrate in the early 20th century, enabling safe storage and large-scale use during World War I.^[4] Advances in pathogen inactivation and screening have reduced infectious transmission risks from historical highs, such as HIV outbreaks in the 1980s, to near-elimination today, though bacterial contamination and transfusion-related acute lung injury persist as notable complications.^[1]^[5] Despite benefits in reducing mortality from exsanguination, transfusions carry inherent risks including immune-mediated hemolysis, allergic responses, and immunomodulation potentially exacerbating infections or cancer recurrence, with peer-reviewed data indicating febrile non-hemolytic reactions in up to 1% of units transfused.^[1]^[6] Patient blood management strategies, emphasizing restrictive thresholds over liberal transfusion policies, reflect causal evidence that unnecessary transfusions confer net harm without proportional survival gains.^[1]

Fundamentals

Definition and Physiological Principles

Blood transfusion constitutes the intravenous administration of whole blood or its fractionated components—such as red blood cells, platelets, or plasma—to a recipient whose physiological homeostasis is disrupted by conditions including hemorrhage, anemia, or coagulopathy.^[1] This process aims to replenish deficits in oxygen transport, primary hemostasis, or coagulation factors, thereby mitigating tissue hypoxia, uncontrolled bleeding, or hypovolemia through direct supplementation of functional blood elements.^[7] Unlike synthetic alternatives, transfusions leverage the inherent biological compatibility of donor-derived cellular and acellular components to integrate into the recipient's circulation, though empirical constraints arise from antigenic mismatches that can precipitate immune-mediated rejection.^[1] At the core of transfusion physiology lies the restoration of oxygen delivery, where red blood cells, laden with hemoglobin, bind molecular oxygen in the pulmonary capillaries and facilitate its diffusion to metabolically active tissues based on partial pressure gradients and the Bohr effect.^[7] In states of acute anemia or blood loss, hemoglobin concentrations below critical thresholds—typically around 7 g/dL in stable adults, though varying by compensatory mechanisms like increased cardiac output—impair this transport, leading to lactic acidosis and organ dysfunction if unaddressed.^[7] Platelets contribute to hemostasis by adhering to vascular endothelium via von Willebrand factor and aggregating through glycoprotein receptors, forming initial plugs that stabilize breaches; their transfusion counters thrombocytopenia where counts fall below 10,000–20,000 per microliter, reducing spontaneous hemorrhage risk via empirical correlations observed in clinical cohorts.^[1] Plasma, comprising water, electrolytes, and labile clotting factors (e.g., fibrinogen, prothrombin), supports fibrin clot formation in the coagulation cascade; its administration addresses deficiencies from massive hemorrhage or liver dysfunction, empirically restoring international normalized ratios toward unity to prevent diffuse microvascular bleeding.^[8] Compatibility hinges on antigenic matching to avert alloimmune responses, primarily governed by the ABO and Rh (D) systems, where surface glycoproteins on erythrocytes elicit pre-formed immunoglobulin M antibodies in non-matching recipients.^[9] ABO incompatibility triggers acute intravascular hemolysis through complement activation and cytokine release, manifesting within minutes as fever, hemoglobinuria, and renal failure, with mortality rates exceeding 5% in severe cases per registry data.^[10] RhD mismatches, lacking natural antibodies, induce delayed extravascular hemolysis via IgG-mediated splenic sequestration upon sensitization, underscoring the causal primacy of antigenic identity in preserving transfused cell viability and function.^[9] These principles reflect the evolutionary adaptation of blood as a closed, self-regulating system intolerant to foreign intrusion without immunological tolerance.^[10]

Blood Components Transfused

Red blood cell (RBC) concentrates, prepared by centrifugation of whole blood to remove plasma and achieve a hematocrit of 55-65%, serve to restore oxygen-carrying capacity.^[11] These units are suspended in additive solutions like AS-1 or CPDA-1, which inhibit glycolysis and hemolysis by providing nutrients such as adenine and dextrose.^[12] Stored at 1-6°C, RBC concentrates maintain viability for 42 days, with FDA standards requiring less than 1% hemolysis at expiration and an average 24-hour posttransfusion recovery exceeding 75%.^[13] ^[14] Platelet concentrates, obtained via apheresis from single donors or pooling from multiple whole blood units, provide hemostatic support by replenishing clotting platelets.^[15] They are stored at 20-24°C with continuous agitation to preserve function and prevent clumping, yielding a shelf life of 5-7 days depending on bacterial testing protocols.^[16] ^[17] Fresh frozen plasma (FFP) is separated from whole blood and frozen within 8 hours of collection to preserve labile coagulation factors.^[18] Containing all plasma proteins including factors II, V, VII, VIII, IX, X, and fibrinogen, FFP is stored at -18°C or colder for up to 1 year.^[19] Cryoprecipitate, derived by controlled thawing of FFP at 1-6°C followed by recentrifugation, concentrates fibrinogen, factor VIII, von Willebrand factor, factor XIII, and fibronectin into a smaller volume.^[20] It is refrozen and stored at -18°C or below, with a shelf life of 1 year.^[21] Whole blood, less commonly fractionated for transfusion in civilian settings but employed in military and prehospital trauma resuscitation, delivers balanced RBCs, plasma, and platelets in their native ratios.^[22] Recent advances have expanded its use in select civilian trauma protocols to mimic physiological hemostasis.^[23]

Component	Key Contents/Roles	Storage Conditions	Shelf Life
RBC Concentrates	Oxygen transport (hematocrit 55-65%)	1-6°C	42 days
Platelet Concentrates	Hemostasis (clotting)	20-24°C, agitated	5-7 days
Fresh Frozen Plasma	Coagulation factors, proteins	≤-18°C	1 year
Cryoprecipitate	Fibrinogen, FVIII, vWF, FXIII, fibronectin	≤-18°C	1 year
Whole Blood	Integrated RBCs, plasma, platelets	1-6°C (limited use)	21-35 days

Clinical Indications and Efficacy

Indications for Red Blood Cell Transfusion

Red blood cell transfusions are indicated to restore oxygen-carrying capacity in patients with severe anemia manifesting as tissue hypoxia, particularly when endogenous compensatory mechanisms such as increased cardiac output and 2,3-diphosphoglycerate levels fail to suffice.^[1] Randomized controlled trials consistently demonstrate that restrictive strategies, triggering transfusion at hemoglobin concentrations of 7 to 8 g/dL in stable patients, are noninferior to liberal approaches (9 to 10 g/dL) in terms of mortality, morbidity, and functional outcomes, while reducing transfusion volumes and associated risks.^[24] The 2023 AABB guidelines recommend a 7 g/dL threshold for most hospitalized adults without active bleeding or specific comorbidities, with a slightly higher 7.5 g/dL for cardiac surgery patients, based on meta-analyses of over 30 trials showing no survival benefit from higher thresholds in stable settings.^[24] ^[25] In acute blood loss from trauma, surgery, or gastrointestinal hemorrhage, initial management prioritizes volume resuscitation with crystalloids, reserving RBC transfusion for persistent hemodynamic instability or hemoglobin below 7 to 8 g/dL post-resuscitation, as liberal transfusion does not reduce mortality and may increase complications like transfusion-related acute lung injury.^[26] ^[27] For instance, in major elective surgery, transfusion is warranted if blood loss exceeds 15 to 30% of estimated blood volume with signs of inadequate oxygen delivery, such as lactic acidosis or end-organ dysfunction.^[28] The TRICS III trial (2017), involving 5,243 cardiac surgery patients, found equivalent 28-day mortality (2.6% restrictive vs. 3.0% liberal) and composite outcomes with a restrictive threshold of 7.5 g/dL versus liberal at 9.5 g/dL.^[29] Symptomatic anemia in critical illness, such as sepsis or acute respiratory distress syndrome, similarly favors restrictive thresholds unless active ischemia is evident, as trials like the 2011 FOCUS study in high-risk hip fracture patients (n=2,016) reported no differences in functional independence or mortality between groups transfused at hemoglobin below 8 g/dL (or symptoms) versus below 10 g/dL.^[30] In oncologic or chronic conditions like chemotherapy-induced anemia, transfusion is reserved for hemoglobin below 7 to 8 g/dL with symptoms of fatigue, dyspnea, or tachycardia attributable to hypoxia, avoiding prophylactic use that lacks outcome benefits.^[28] The REALITY trial (2018, n=668 AMI patients with anemia) confirmed noninferiority of a restrictive (≤8 g/dL) versus liberal (≤10 g/dL) strategy for 30-day major cardiovascular events, supporting application in ischemic settings without routine higher thresholds.^[31] Overall, causal evidence links RBC transfusion efficacy to correction of profound oxygen debt rather than mild hemodilution, where physiologic adaptations predominate; overuse in asymptomatic patients correlates with net harm from immunomodulation and iron overload without offsetting gains.^[24] ^[1]

Indications for Platelet and Plasma Transfusion

Platelet transfusions are primarily indicated for patients with severe thrombocytopenia and active bleeding, or prophylactically in stable patients at high risk of spontaneous hemorrhage. According to AABB guidelines, prophylactic transfusion is recommended for hospitalized adults with platelet counts of 10 × 10⁹/L or less to mitigate bleeding risk, particularly in those with hypoproliferative thrombocytopenia from chemotherapy or hematologic malignancies.^[32] For patients undergoing invasive procedures or surgery, a higher threshold of 50 × 10⁹/L is advised to prevent perioperative bleeding, while counts below 20 × 10⁹/L warrant transfusion prior to neuraxial procedures like lumbar puncture.^[33] These thresholds derive from randomized trials and observational data emphasizing restrictive strategies, as liberal prophylactic transfusion in non-bleeding patients with counts above 10 × 10⁹/L does not demonstrably reduce clinically significant hemorrhage and increases exposure to transfusion risks such as alloimmunization.^[32] Platelets function causally in hemostasis by adhering to damaged endothelium and aggregating to form plugs, but in stable thrombocytopenia without bleeding, endogenous compensatory mechanisms often suffice, rendering routine transfusion unnecessary absent empirical support.^[34] Fresh frozen plasma (FFP) transfusions are reserved for correcting coagulopathy due to multiple factor deficiencies in the setting of active bleeding or high bleeding risk prior to invasive procedures. Guidelines specify FFP for patients with abnormal coagulation tests (e.g., INR >1.5) and clinically significant bleeding, such as in warfarin reversal when vitamin K or prothrombin complex concentrates are unavailable or insufficient, or in dilutional coagulopathy from non-massive hemorrhage.^[35] Prophylactic FFP is not indicated for isolated elevations in INR or PTT without bleeding, as trials including subgroup analyses from the PROPPR study demonstrate no mortality or hemostatic benefit in non-massive bleeding scenarios, where plasma transfusion fails to correct underlying deficits more effectively than targeted factor replacement.^[36] In non-hemorrhagic patients, FFP administration correlates with overuse, driven by laboratory abnormalities rather than causal coagulopathy, leading to unnecessary risks without improving outcomes.^[37] Plasma provides clotting factors to restore thrombin generation and fibrin formation, but its volume load and dilutional effects limit utility outside acute, multifactor-deficient states.^[38]

Massive Transfusion Protocols

Massive transfusion protocols (MTPs) are standardized systems designed to deliver rapid, high-volume blood product resuscitation to patients with life-threatening hemorrhage, typically in trauma or perioperative settings involving exsanguination. These protocols aim to restore circulating volume, correct coagulopathy, and achieve hemostatic balance by empirically providing fixed ratios of blood components early in resuscitation, followed by goal-directed adjustments. Massive transfusion is commonly defined as the administration of 10 or more units of packed red blood cells (PRBCs) within 24 hours or replacement of one total blood volume (approximately 70 mL/kg or 5 liters in adults) in the same period.^[39]^[40] A cornerstone of modern MTPs is the 1:1:1 ratio of PRBCs to plasma to platelets, derived from military experiences in Iraq and Afghanistan and validated in civilian trauma by the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial conducted from 2011 to 2013 across 12 U.S. Level I trauma centers. In this phase 3 randomized trial involving 680 patients predicted to require massive transfusion, the 1:1:1 group achieved higher rates of hemostasis (86% vs. 61%) and lower 24-hour mortality due to exsanguination (9.2% vs. 14.6%) compared to a 1:1:2 ratio, though overall 30-day mortality differences were not statistically significant (21.9% vs. 26.7%).^[36] This ratio mimics whole blood composition to mitigate trauma-induced coagulopathy, reducing dilutional effects from crystalloids or unbalanced PRBCs alone, and has been adopted in guidelines from organizations like the American College of Surgeons.^[41] Advancements in 2024-2025 emphasize viscoelastic hemostatic assays (VHAs) such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for transitioning from empirical fixed-ratio activation to individualized, goal-directed therapy within MTPs. These point-of-care tests assess whole-blood clot formation, strength, and lysis in real time, enabling targeted administration of fibrinogen, platelets, or antifibrinolytics to address specific deficits, which reduces overall blood product use by 20-30% and multiorgan failure rates compared to conventional testing. A 2024 Surgical Critical Care Initiative guideline recommends VHA-guided MTP activation thresholds, such as prolonged reaction time (>10 minutes on TEG) or low maximum amplitude (<50 mm), to limit unnecessary transfusions while improving survival in coagulopathic patients.^[42] Prehospital extensions of MTP principles, particularly low-titer O whole blood transfusion, have shown survival benefits in both military and civilian austere environments by enabling early hemostatic resuscitation before hospital arrival. Military data from forward surgical teams indicate 2-3 times higher 30-day survival with prehospital whole blood versus component therapy alone in hemorrhagic shock. In U.S. civilian settings, expanded EMS access to whole blood correlates with 60% reduced 24-hour mortality in severe trauma, per a 2024 JAMA Surgery cohort analysis. The American College of Surgeons estimates that universal prehospital blood availability could prevent approximately 10,000 annual U.S. trauma deaths, primarily from preventable hemorrhagic shock in transport delays exceeding 20 minutes.^[43]^[44]

Evidence on Transfusion Efficacy and Thresholds

Multiple randomized controlled trials and meta-analyses have demonstrated that restrictive red blood cell transfusion strategies, typically triggering at hemoglobin levels below 7-8 g/dL, are noninferior to liberal strategies (thresholds of 9-10 g/dL) in terms of mortality and major morbidity among critically ill adults.^[45]^[46] A 2024 meta-analysis of ICU patients found no significant short-term mortality difference between the two approaches, with restrictive strategies reducing transfusion exposure without compromising outcomes in stable cases.^[45] Similarly, the 2021 Cochrane review of transfusion thresholds confirmed that restrictive policies (7-8 g/dL) yield equivalent or lower risks of death, cardiac events, and infections compared to liberal ones across diverse settings, including perioperative and ICU contexts.^[46] In pediatric intensive care, the TRIPICU trial established that withholding transfusions in hemodynamically stable children with hemoglobin above 7 g/dL does not worsen outcomes, supporting restrictive thresholds as safe and effective for reducing unnecessary exposures.^[47] Subsequent meta-analyses in critically ill children reinforce this, showing restrictive strategies significantly lower nosocomial infection rates without increasing mortality or length of stay.^[48] For cardiac surgery patients, the 2017 TRICS-III trial reported noninferiority of restrictive versus liberal transfusion for composite outcomes like death and major complications, though subgroup analyses in high-risk cardiovascular disease suggest potential elevated myocardial infarction risks with overly restrictive approaches below 8 g/dL.^[29]^[49] Overall, liberal strategies fail to demonstrate consistent superiority, with no reductions in 30-day mortality across pooled data from trials like FOCUS and REALITY.^[50]^[51] Transfusion overuse contributes to silent harms, including immunomodulation that elevates postoperative infection risks and volume-related complications like transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI).^[52] Restrictive approaches mitigate these by limiting exposures, as evidenced by reduced acute reactions in permissive versus restrictive comparisons.^[52] The UK's 2024 Serious Hazards of Transfusion (SHOT) report documented a 33.9% rise in avoidable transfusions to 170 cases, alongside a 47% increase in delays, underscoring systemic overuse despite evidence favoring targeted administration as a temporary oxygen bridge rather than a therapeutic cure-all.^[53] Cohort studies in cardiac surgery link cumulative liberal transfusions to accumulated harms, including higher infection and organ dysfunction rates, reinforcing data-driven thresholds to avoid net detriment.^[54]

Procedure

Blood Donation and Collection

Blood donation primarily occurs through voluntary, non-remunerated models in countries like the United States, where donors are motivated by altruism rather than financial incentives, contributing to lower rates of infectious disease markers compared to compensated systems.^[55]^[56] Whole blood donation involves collecting approximately 450-480 mL of blood via venipuncture from the antecubital vein, a process lasting 8-15 minutes during which donors are encouraged to rhythmically open and close their fist to promote blood flow.^[57]^[58] Apheresis donation, by contrast, uses automated machines to selectively collect components such as platelets or plasma while returning other elements to the donor, typically requiring 1-2 hours and allowing more frequent participation for certain products.^[59]^[60] Prior to phlebotomy, donors undergo rigorous screening to ensure eligibility and safety, including a standardized health questionnaire assessing recent travel to endemic areas (e.g., malaria deferral for 12 months post-residency), infections, medications, vaccinations, and high-risk behaviors, with temporary or permanent deferrals applied as needed.^[61]^[62] Hemoglobin levels must meet minimum thresholds of 12.5 g/dL for females and 13.0 g/dL for males to prevent donation-induced anemia, verified via fingerstick or venous sampling.^[63]^[64] Empirical data indicate blood donation is safe for healthy donors, with adverse events like vasovagal reactions occurring in less than 1% of cases, though frequent whole blood donors face iron depletion risks due to loss of 200-250 mg of iron per unit from red cell donation.^[65] This depletion, more prevalent in premenopausal women and multiparous donors, can lead to iron deficiency without anemia in up to 20-30% of regular donors, mitigated by inter-donation intervals of at least 56 days, selective ferritin testing, and iron supplementation protocols for high-frequency donors.^[66]^[67] Compensated models, common for plasma collection, show mixed safety outcomes but have not demonstrably improved supply sustainability or reduced infectious risks compared to altruistic systems.^[68] Recent trends reflect persistent challenges in donor recruitment despite targeted campaigns; for instance, the American Red Cross reported the lowest donor turnout in 20 years by early 2024, leading to emergency shortages, while community blood centers like those affiliated with America's Blood Centers noted fluctuating transfusion demands amid ongoing supply constraints into 2025.^[69]^[70] Only about 3% of eligible U.S. individuals donate annually, exacerbating shortages during high-demand periods like summer.^[71]

Processing, Testing, and Storage

Whole blood collected from donors undergoes centrifugation to separate it into components such as red blood cells (RBCs), platelets, and plasma. This process typically involves initial sedimentation or automated centrifugation systems that exploit density differences, yielding RBC units by removing most plasma while retaining additive solutions for preservation.^[72] Leukoreduction, often performed pre-storage via inline filtration, removes over 99% of leukocytes to mitigate febrile non-hemolytic transfusion reactions and cytomegalovirus transmission risks.^[73] Post-processing, units are tested for infectious agents using nucleic acid testing (NAT) via polymerase chain reaction (PCR) to detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) during their respective window periods—the interval between infection and serological detectability. NAT implementation has reduced these windows to approximately 5-12 days for HIV and HCV, and about 21-30 days for HBV in minipool formats, enabling earlier identification of contaminated units compared to serological methods alone.^[74] ^[75] For platelets, bacterial contamination risks—arising from room-temperature storage favoring microbial growth—are addressed through culture-based screening (e.g., 24-36 hour aerobic/anaerobic incubation) or rapid detection assays like the Platelet PGD test, which identifies gram-positive and gram-negative bacteria within hours of potential transfusion.^[76] ^[77] ^[78] RBC components are stored at 1-6°C in validated additive solutions such as AS-1 (Adsol) or SAGM (saline-adenine-glucose-mannitol), which provide nutrients to maintain cellular integrity and extend shelf life to 42 days while limiting hemolysis to under 1% at expiration.^[11] Platelets require storage at 20-24°C in gas-permeable containers with continuous gentle agitation (e.g., via flatbed shakers at 50-60 cycles per minute) to prevent clumping, ensure oxygen diffusion, and preserve functionality, with a shelf life of 5 days for pooled units and 7 days for apheresis-derived products.^[79] ^[80] Emerging pathogen reduction technologies, such as the INTERCEPT Blood System, employ amotosalen and ultraviolet A light to inactivate viruses, bacteria, protozoa, and residual leukocytes in platelets and plasma, reducing septic transfusion risks by targeting contaminants throughout storage duration. Evaluations in 2024 confirm high inactivation efficacy against bacteria in platelet concentrates up to end-of-shelf-life, even when combined with bacterial detection methods, supporting broader adoption to enhance safety without relying solely on donor deferrals or testing windows.^[81] ^[82]

Compatibility Testing and Administration

Compatibility testing for blood transfusion ensures ABO and RhD compatibility between donor and recipient to prevent hemolytic reactions, involving serological determination of the patient's blood group via forward typing of red blood cells with anti-A, anti-B, and anti-D reagents, confirmed by reverse typing of plasma with A1 and B cells.^[83] An antibody screen tests the patient's plasma against 2-3 reagent red cell panels expressing multiple antigens to detect unexpected IgM or IgG alloantibodies, with positive results requiring identification and antigen-negative unit selection.^[83] The crossmatch mixes donor red cells with patient serum, assessing compatibility through immediate spin (for ABO incompatibility), 37°C incubation (for IgM), and anti-human globulin (AHG) phase (for IgG-coated cells indicating incomplete antibodies); minor crossmatches are obsolete per AABB standards since 1976 due to low risk from donor plasma antibodies.^[84] ^[85] Electronic crossmatch, permitted under AABB and FDA guidelines, substitutes serological crossmatch when the patient has a negative antibody screen, two historical ABO/Rh records matching current typing, and no clinically significant antibodies, relying on computerized verification of ABO compatibility to expedite release for low-risk cases.^[86] ^[87] In emergencies like trauma or massive hemorrhage, uncrossmatched type O RhD-negative red cells serve as universal donor units if the patient's type is unknown, transitioning to type-specific uncrossmatched blood once typing is available, though RhD-positive units risk alloimmunization in RhD-negative females of childbearing potential.^[88] ^[89] Administration requires informed consent, large-bore IV access (18-20 gauge), and infusion via a dedicated line with a 170-μm microaggregate filter to prevent microclots, starting at 1-2 mL/min for the first 15 minutes under close observation, then increasing to 2-4 mL/kg/hour or completing one unit of packed red cells over 1-4 hours based on patient stability.^[1] Vital signs (temperature, pulse, respiration, blood pressure) are monitored pre-transfusion, at 15 minutes, then hourly until completion, with immediate cessation and reporting if reactions occur.^[90] Recent advancements include point-of-care genotyping devices for rapid ABO/RhD determination in 2024-2025, enabling faster compatibility in resource-limited or emergency settings by direct DNA analysis from fingerstick samples, reducing reliance on serological methods.^[91] ^[92]

Risks and Complications

Acute Immunologic Reactions

Acute immunologic reactions to blood transfusion involve recipient or donor antibodies targeting incompatible antigens on transfused cells or soluble factors, leading to rapid activation of immune cascades such as complement-mediated hemolysis or cytokine release. These occur within 24 hours of transfusion initiation and include acute hemolytic transfusion reactions (AHTR), febrile non-hemolytic transfusion reactions (FNHTR), anaphylactic reactions, and transfusion-related acute lung injury (TRALI). Causal mechanisms center on antibody-antigen binding, triggering endothelial damage, leukocyte aggregation, or mast cell degranulation, with empirical evidence from hemovigilance data showing higher risks in mismatched or unscreened units.^[93] AHTR primarily results from ABO-incompatible red blood cell transfusions, where pre-existing isohemagglutinins bind donor erythrocytes, activating complement and causing intravascular hemolysis, hemoglobinuria, and potential renal failure or disseminated intravascular coagulation. Incidence is estimated at 1 in 38,000 to 70,000 transfusions, predominantly due to clerical errors in compatibility testing rather than inherent serological failures, with fatality rates around 1 in 1 million transfusions linked to severe cases involving large-volume mismatches.^[94]^[95] FNHTR manifests as fever and chills from recipient antibodies against donor leukocytes or accumulated cytokines in stored products, without hemolysis, occurring in 1-2% of transfusions and more frequently with platelet units due to higher cytokine loads.^[96] Anaphylactic reactions, though rare at 1 in 20,000-47,000 transfusions, arise mainly in IgA-deficient recipients with anti-IgA antibodies reacting to donor IgA, causing hypotension, bronchospasm, and urticaria via IgE-independent or mast cell-mediated pathways.^[97] TRALI involves donor anti-HLA or anti-human neutrophil antigen (HNA) antibodies priming recipient neutrophils in pulmonary capillaries, leading to sequestration, oxidative damage, and non-cardiogenic edema, with incidence approximately 1 in 5,000 transfusions and mortality of 5-10%, higher in critically ill patients.^[98]^[99] Management for all types mandates immediate cessation of transfusion, intravenous fluids, vasopressors if needed, and supportive care like oxygen or diuretics, while notifying the blood bank for clerical checks, direct antiglobulin testing, and plasma-free hemoglobin assays to confirm etiology.^[93] Prevention relies on rigorous ABO/Rh typing and cross-matching for AHTR, leukocyte-reduced products for FNHTR and allergic reactions, and empirical donor screening—such as deferring multiparous females for plasma components—to mitigate TRALI, which has reduced cases post-implementation in high-risk pools.^[100]

Infectious Transmission Risks

In high-income countries like the United States, rigorous donor screening, nucleic acid testing (NAT), and serologic assays have reduced the residual risk of viral transmission via blood transfusion to extremely low levels, primarily attributable to donations occurring during the eclipse or window period of donor viremia before detectability. For HIV, the window-period residual risk (WPRR) per million donations was estimated at 0.08 (95% CI: 0.02–0.17) in 2022–2023, equivalent to approximately 1 in 12.5 million units. Similar estimates for HCV yielded risks below 1 in 5 million, while HBV risks were slightly higher at around 0.31 per million (1 in 3.2 million), reflecting longer window periods for occult HBV infections.^[101] These figures represent a substantial decline from pre-NAT eras, where HIV risks exceeded 1 in 100,000, underscoring the efficacy of multiplex NAT implemented since the late 1990s in closing detection gaps caused by viral replication dynamics.^[102] Bacterial contamination poses a more persistent infectious hazard, particularly for platelets stored at room temperature, which permit bacterial proliferation from skin flora or asymptomatic donor bacteremia. Prior to widespread culture-based screening, clinically significant contamination rates in platelet units approached 1 in 5,000–10,000, contributing to septic transfusion reactions at rates of 1 in 50,000 or higher and remaining the second leading cause of transfusion-related infectious deaths in the US.^[103] ^[77] Modern mitigations, including automated culturing (e.g., 24–36 hour aerobic/anaerobic sampling) and pathogen reduction technologies (PRT) like amotosalen/UVA or riboflavin/UV light, have lowered these risks by inactivating bacteria and enveloped viruses through nucleic acid cross-linking, with PRT demonstrating near-complete elimination of bacterial growth in treated platelets without compromising hemostatic function in clinical trials.^[82] ^[104] Emerging pathogens, such as variant Creutzfeldt-Jakob disease (vCJD), highlight ongoing challenges from non-enveloped prions resistant to standard testing; however, post-2000 leukoreduction and donor deferrals for UK exposure have rendered transfusion-transmission risks negligible, with no confirmed US cases and modeling estimating probabilities below 1 in 1 billion for screened components.^[105] Claims regarding heightened risks from unvaccinated directed donations—occasionally raised in 2023–2025 discussions amid COVID-19 vaccine debates—lack empirical support, as vaccines do not introduce replicative pathogens and no transfusion-transmitted vaccine-related infections have been documented, with residual risks tied instead to undetected donor infections irrespective of vaccination status.^[106] In low-resource settings, infectious risks remain markedly elevated due to incomplete NAT implementation, higher community prevalence of endemic pathogens like HBV and HCV, and reliance on family replacement donors with undisclosed behaviors, yielding TTI rates 10–100 times higher than in high-income nations—for instance, HBV seroprevalence in donations often exceeds 5–10% versus <0.5% in the US.^[107] ^[108] Historical outbreaks, such as the 1980s HIV epidemic via unscreened transfusions, reinforce the causal primacy of testing infrastructure over donor selection alone in averting transmissions.^[109]

Non-Infectious Complications and Inefficacy

Transfusion-related immunomodulation (TRIM) encompasses immunosuppressive effects from allogeneic blood components, potentially elevating risks of postoperative infections and cancer recurrence through mechanisms like soluble biologic response modifiers and white blood cell microaggregates. Observational studies link perioperative transfusions to a 20-30% higher infection risk in surgical patients.^[110] In cancer contexts, TRIM correlates with increased recurrence, as evidenced by randomized trials in colorectal surgery showing poorer outcomes with transfusions.^[110] These associations persist despite confounding factors like disease severity, though causality remains debated due to reliance on non-randomized data.^[111] Red blood cell storage lesions, accumulating over 42-day shelf life, include 2,3-diphosphoglycerate (2,3-DPG) depletion, which reduces hemoglobin's oxygen offloading capacity by shifting the dissociation curve leftward and impairing tissue oxygenation. Stored units lose 65-85% of 2,3-DPG within 14 days, compromising immediate post-transfusion efficacy despite potential rapid replenishment in vivo.^[112] Additional lesions like hemolysis and membrane rigidity further limit microvascular perfusion, contributing to net inefficacy in non-hypoxic states.^[113] Transfusion-associated circulatory overload (TACO), distinct from acute immunologic reactions, arises from rapid volume expansion precipitating hydrostatic pulmonary edema, hypertension, and tachycardia, especially in patients with heart failure or renal dysfunction. Incidence exceeds 1% in at-risk groups, with risk factors including older age and multiple-unit infusions.^[114] Beyond TACO, chronic volume challenges from overtransfusion exacerbate cardiac strain in vulnerable populations. Iron overload from repeated transfusions, particularly in hematologic disorders, deposits excess ferritin in organs, fostering cardiomyopathy, hepatic fibrosis, and endocrine dysfunction via oxidative stress.^[115] Empirical evidence underscores transfusion inefficacy in mild anemia, with meta-analyses of randomized trials demonstrating that restrictive strategies (transfusing at hemoglobin <7-8 g/dL) halve usage volumes versus liberal approaches without elevating mortality, morbidity, or ischemic events.^[46] U.S. hospitalization data reflect this shift, with red blood cell transfusion rates falling from 6.8% in 2011 to 5.7% in 2014—a 16% relative decline—attributable to guideline adoption and yielding no population-level harm signals.^[116] Such reductions, approaching 20-30% in select cohorts like oncology, affirm minimal net benefit from routine transfusions in stable, non-bleeding patients.^[117]

Long-Term Outcomes and Overtransfusion Evidence

Blood transfusions have been associated with increased long-term mortality in multiple patient cohorts, including those undergoing cardiac surgery and cancer treatment. A 2024 study analyzing adult patients found that transfusion significantly elevates all-cause and cardiovascular mortality risks, positioning it as an underrecognized factor in post-transfusion survival.^[118] Similarly, in cardiac surgery patients, transfusions correlate with heightened early and late mortality extending up to five years postoperatively.^[119] Cohort data from coronary artery bypass grafting indicate that perioperative transfusions independently predict reduced long-term survival, independent of initial hemoglobin levels or comorbidities.^[120] Longitudinal evidence links transfusions to accumulating harms, such as sepsis and multiple organ failure (MOF), particularly with stored allogeneic blood products. Transfusion of older red blood cells has been tied to higher rates of complicated sepsis and MOF in trauma patients, with mechanistic hypotheses involving inflammatory responses from storage lesions.^[121] Fresh frozen plasma and platelet transfusions independently associate with MOF development in critically injured individuals, beyond volume effects.^[122] Reviews from 2008 onward, including in sepsis and heart failure contexts, have failed to demonstrate net survival benefits from liberal transfusion practices, often highlighting null or adverse outcomes.^[123] Overtransfusion, frequently perpetuated by habitual adherence to outdated thresholds rather than patient-specific needs, contributes to these risks. Randomized trials and meta-analyses consistently support restrictive strategies (e.g., hemoglobin thresholds of 7-8 g/dL) as noninferior or superior to liberal approaches in reducing transfusion volumes without compromising outcomes, including in myocardial infarction and critically ill patients.^[124] A 2023 Nature Medicine trial underscored hemoglobin differentials favoring restriction, with lower transfusion exposure linked to fewer adverse events. The UK's 2024 Serious Hazards of Transfusion (SHOT) report documented rising avoidable transfusions, with delays and errors contributing to doubled transfusion-related deaths year-over-year, emphasizing systemic overutilization.^[125] Autologous transfusions mitigate alloimmunization and immunomodulatory risks inherent to allogeneic products, showing preferable immune profiles and outcomes where feasible. Intraoperative autologous use demonstrates less suppression of immune function compared to allogeneic, potentially improving relapse-free survival in surgical oncology.^[126] Propensity-matched analyses confirm autologous strategies avoid the long-term survival decrement observed with allogeneic transfusions in adjusted models.^[127]

Historical Development

Pre-20th Century Attempts

In the mid-17th century, early experiments with blood transfusion emerged from animal studies, with English physician Richard Lower demonstrating successful dog-to-dog transfusions in 1665 using quills and veins, which inspired human applications.^[128] French physician Jean-Baptiste Denis conducted the first documented human transfusion on June 15, 1667, infusing about 12 ounces of lamb blood into a 15-year-old boy suffering from fever, who reportedly recovered initially without immediate adverse effects.^[129] Subsequent attempts by Denis, including two transfusions to patient Antoine Mauroy in late 1667, resulted in severe reactions such as back pain, abdominal cramps, and dark urine indicative of hemoglobinuria, followed by Mauroy's death, which empirical observation attributed to the procedure.^[130] These xenotransfusions—transferring animal blood to humans—frequently failed due to profound incompatibility, causing intravascular hemolysis where recipient antibodies destroyed foreign red cells, releasing hemoglobin and triggering coagulopathy through activation of clotting cascades and consumption of factors.^[131] In England, similar lamb-to-human trials, such as one on Arthur Coga by Edmund King under Royal Society auspices in November 1667, yielded no therapeutic benefit and highlighted risks like air embolism from primitive apparatus.^[130] The empirical toll, including multiple fatalities, prompted the Paris Parlement to ban transfusions in France in January 1668 without Faculty of Medicine approval, effectively halting practice amid political and medical disputes; analogous discouragement in England led to a near-total cessation by the 1670s.^[130]^[132] The 18th century saw virtual abandonment of transfusions owing to these documented failures and lack of understanding of blood compatibility, with isolated reports of animal blood use dismissed as ineffective or harmful. Revival occurred in the early 19th century, driven by obstetric needs; British physician James Blundell, motivated by maternal hemorrhage deaths, developed an impellor syringe for human-to-human transfer and performed the first recorded successful such transfusion on August 26, 1818, salvaging a postpartum patient with blood from three donors, though he noted subsequent cases often failed from unknown causes like sudden collapse or renal issues.^[128] Blundell's 10 human transfusions between 1818 and 1825 had a roughly 50% success rate, with failures empirically linked to immediate reactions such as fever and hemoglobinuria, later attributable to undiscovered ABO antigen mismatches causing agglutination and hemolysis.^[4] By mid-century, accumulated evidence of high mortality—exacerbated by coagulopathy from incompatible plasma and technical risks like clotting in cannulas—led to formal prohibitions on animal-to-human trials in several European jurisdictions and widespread medical skepticism, stalling progress until antigen discovery.^[131]

World Wars and Early Blood Banking

During World War I, the introduction of sodium citrate as an anticoagulant enabled indirect blood transfusions and short-term storage, marking a pivotal shift from direct arm-to-arm methods. In 1914, Albert Hustin in Belgium and Luis Agote in Argentina independently demonstrated that adding sodium citrate to blood prevented clotting, allowing collection and delayed administration.^[133]^[134] Richard Lewisohn in New York confirmed its clinical safety in 1915, facilitating transfusions without immediate donor presence.^[133] These advances, driven by battlefield hemorrhagic shock, were scaled by U.S. Army Captain Oswald Hope Robertson, who established mobile blood depots supplying citrated, refrigerated, group O whole blood tested for syphilis.^[135]^[128] Robertson's units, operational from 1917 at forward stations like the British front, stored blood for up to 26 days and reduced mortality from exsanguination by enabling rapid, logistically feasible resuscitation.^[135]^[136] World War II amplified these techniques amid massive casualties, with military necessity spurring preservation innovations for remote delivery. The U.S. Army adopted dried human plasma as a lightweight, stable alternative to whole blood, dehydrated after separation and reconstitutable with water at aid stations.^[137]^[138] By 1940, protocols emphasized early plasma infusion to restore volume in shock, followed by refrigerated whole blood shipped in fridges from stateside banks; the American Red Cross processed over 13 million pints, yielding millions of plasma units for overseas use.^[139]^[140] Theater blood banks, like those at the 15th Medical General Laboratory, supplied citrated whole blood via mobile refrigerators, cutting transport times and enabling forward transfusions that lowered hemorrhagic shock fatalities compared to World War I rates.^[139]^[141] These causal logistics—refrigeration for whole blood viability and plasma's shelf stability—directly addressed exsanguination by sustaining circulation until surgical intervention, with empirical observations noting improved survival in penetrating trauma.^[142]^[143] In the late 1940s, wartime experiences prompted U.S. civilian blood banking expansion, with community centers adopting military-derived storage and typing protocols to stockpile universal donor units.^[128]^[139] This infrastructure, tested in combat for efficacy in reducing shock mortality, laid foundations for peacetime reserves without relying on on-site donors.^[141]

Post-War Advances and Modern Standardization

In the 1950s, the shift from glass bottles to plastic polyvinyl chloride bags revolutionized blood collection and storage, enabling easier handling, reduced contamination risks, and the potential for component separation; this innovation, pioneered by Carl Walter and W.P. Murphy Jr. in 1950, facilitated closed-system processing that extended usability and minimized bacterial ingress.^[128]^[144] Concurrently, citrate-phosphate-dextrose (CPD) solution replaced acid-citrate-dextrose (ACD), improving red blood cell viability with a 21-day shelf life by better preserving adenosine triphosphate levels, becoming the U.S. standard for whole blood from 1957 to 1979.^[145] The 1980s HIV/AIDS epidemic, which infected thousands via unscreened transfusions before antibody tests were implemented in 1985, catalyzed stringent donor deferral policies, surrogate viral marker testing, and eventual nucleic acid testing (NAT); NAT, introduced for hepatitis C in 1999 and HIV in 2000s, detects viral genomes directly, reducing window-period transmissions to below 1 in 1.5 million donations.^[146]^[147] These measures, alongside leukoreduction filters adopted widely by the late 1990s, plummeted infectious risks, with overall transfusion-transmitted infection rates falling from thousands of cases pre-1985 to 0.23 per 100,000 units by 2017 for HIV, hepatitis B, and hepatitis C combined.^[148] Standardization advanced through organizations like the American Association of Blood Banks (AABB, now AABB) and FDA regulations, which mandate donor screening, infectious disease testing, and compatibility verification under 21 CFR 606; AABB standards, updated periodically, emphasize quality systems for collection, processing, and transfusion to ensure <0.1% rates for severe hemolytic reactions via improved ABO/Rh typing and crossmatching.^[149]^[150] Empirical data reflect this: acute transfusion reaction incidences dropped from approximately 1-2% in mid-20th-century reports (driven by incomplete typing) to 0.5-0.6% overall by the 2020s, with fatal events rarer than 1 in 100,000 units due to hemovigilance and electronic verification.^[151]^[152] Recent refinements include molecular genotyping for blood group antigens, resolving serological ambiguities in 10-20% of complex cases, and pathogen reduction technologies (PRT) like INTERCEPT, which use amotosalen/UVA to inactivate viruses, bacteria, and parasites in platelets and plasma; FDA-approved PRT implementations in the 2020s further mitigate emerging threats, though adoption varies due to cost and efficacy data showing 4-6 log pathogen reduction.^[153] Massive transfusion protocols (MTPs), standardized for trauma with 1:1:1 ratios of plasma:platelets:red cells, integrated into Veterans Health Administration (VHA) patient blood management directives by 2024, emphasize restrictive thresholds and viscoelastic hemostasis testing to curb overtransfusion while sustaining survival rates above 50% in exsanguinating cases.^[154]^[155]

Special Populations

Neonates and Pediatrics

Blood transfusions in neonates necessitate precise volume adjustments due to their limited circulating blood volume, typically 85-100 mL/kg in preterm and full-term infants, respectively, to avoid circulatory overload.^[156]^[157] Standard red blood cell (RBC) transfusion volumes are calculated as 10-15 mL/kg, which approximates a 2-3 g/dL increase in hemoglobin, using formulas such as weight (kg) × desired hemoglobin increment (g/dL) × 3 / hematocrit of the RBC unit.^[158]^[159] Products are often fresh (≤7 days old), leukoreduced, and suspended in additive solutions compatible with small-volume administration, minimizing potassium and additive-related toxicities.^[160] Neonates face elevated risks of transfusion-associated graft-versus-host disease (TA-GVHD) from donor T-lymphocytes proliferating in their immature immune systems, with preterm infants under 4 months or those receiving intrauterine transfusions at particular vulnerability; irradiation of cellular components at 25 Gy prevents lymphocyte replication and is standard prophylaxis, though it may elevate extracellular potassium, necessitating fresh irradiation (within 24-48 hours of transfusion).^[161]^[162]^[163] Transfusion-transmitted cytomegalovirus (TT-CMV) risk prompts use of CMV-seronegative or leukoreduced blood products, particularly for low-birth-weight infants, as seroprevalence in donors can exceed 50% and neonatal infection correlates with severe morbidity.^[163]^[164] Restrictive transfusion thresholds are supported by randomized trials in preterm neonates, demonstrating safety at hemoglobin levels of 7-8 g/dL for stable infants versus liberal thresholds of 11-13 g/dL, with no differences in mortality, neurodevelopment, or retinopathy of prematurity; for example, the 2020 TOP trial found higher transfusion needs but equivalent survival with liberal strategies.^[165]^[166] A 2024 consensus recommends restrictive approaches for preterm neonates under 30 weeks' gestation, citing moderate evidence from meta-analyses showing reduced nosocomial infections without increased adverse outcomes.^[167] In pediatrics beyond the neonatal period, transfusions account for immature physiology and frequent phlebotomy losses, with RBC volumes similarly dosed at 10-15 mL/kg and thresholds around 7 g/dL in hemodynamically stable critically ill children, per intensive care trials indicating noninferiority to higher thresholds in reducing transfusions while preserving outcomes.^[168]^[48] Irradiation remains indicated for immunocompromised children or those with fetal hemoglobin persistence, but routine use is avoided in stable outpatients to prevent storage lesions; platelet transfusions, when needed, use 10 mL/kg doses to achieve increments of 20,000-50,000/μL.^[169]^[160]

Trauma and Acute Blood Loss

In trauma patients experiencing acute blood loss from hemorrhagic shock, permissive hypotension—maintaining systolic blood pressure around 90 mmHg until definitive hemostasis—is employed to minimize further bleeding by avoiding disruption of nascent clots formed under low pressure, thereby reducing total blood loss and improving survival compared to aggressive fluid resuscitation targeting normal blood pressure.^[170]^[171] This approach, rooted in limiting shear stress on vascular repair sites, contrasts with historical normotensive targets that exacerbate hemorrhage through clot dislodgement, as evidenced by meta-analyses showing halved mortality risk and decreased organ dysfunction with permissive strategies in penetrating and blunt injuries.^[172] However, it requires vigilant monitoring to prevent ischemic complications, particularly in patients without traumatic brain injury, where cerebral perfusion thresholds demand higher pressures.^[173] Damage control resuscitation prioritizes early administration of blood products in balanced ratios to restore hemostasis without diluting coagulation factors, as excessive crystalloid volumes induce dilutional coagulopathy by reducing thrombin generation and factor concentrations through hemodilution and inflammatory activation.^[174]^[175] The PROPPR trial demonstrated that a 1:1:1 ratio of plasma, platelets, and red blood cells—mimicking whole blood's composition—lowered deaths from exsanguination at 24 hours (9.2% vs. 14.6%) compared to a 1:1:2 ratio, with similar overall 30-day mortality but superior hemorrhage control in severe trauma requiring massive transfusion.^[36]^[176] This causal mechanism stems from preempting factor depletion and platelet dysfunction, which crystalloids fail to address, leading to persistent microvascular bleeding.^[177] Tranexamic acid serves as an adjunct by inhibiting fibrinolysis, reducing bleeding deaths when administered within three hours of injury, as shown in the CRASH-2 trial's 1.5% absolute mortality reduction and confirmed in prehospital settings with no increased vascular occlusion risk.^[178] Integrated into protocols alongside balanced transfusions, it enhances clot stability without replacing blood volume restoration.^[179] Prehospital transfusion of whole blood, often low-titer O group, has emerged as optimal for early resuscitation, with faster initiation correlating to survival gains; delays beyond one hour elevate 24-hour mortality odds, while whole blood outperforms component therapy by preserving native coagulation synergy.^[43]^[180] In the U.S., expanded prehospital access could avert approximately 10,000 trauma deaths annually by bridging to hospital care, based on cohort data showing 60% mortality reductions at 24 hours with field administration versus crystalloids alone.^[44]^[181] These empiric outcomes underscore causal prioritization of oxygen-carrying, hemostatic resuscitation over volume expansion, transforming prehospital protocols in high-hemorrhage scenarios like motor vehicle collisions and penetrating wounds.^[182]

Patients with Unknown Blood Type

In emergency scenarios where a patient's ABO and RhD blood type cannot be determined prior to transfusion, uncrossmatched group O RhD-negative red blood cell concentrates are standardly administered as the universal donor product, limited typically to 1-2 units to bridge until typing is completed.^[183]^[184] This approach minimizes transfusion delays while averting acute hemolytic reactions, as group O RhD-negative erythrocytes lack A, B, and RhD antigens that could trigger recipient isohemagglutinins.^[185] For male patients or females beyond childbearing age, group O RhD-positive units may be substituted after initial O-negative dosing to conserve limited O-negative inventory, given the low risk of RhD alloimmunization in these groups.^[186]^[187] Low-titer group O whole blood, with anti-A and anti-B isohemagglutinin titers below 1:256, extends this empirical strategy by providing plasma, platelets, and red cells in a single unit suitable for unknown recipients, particularly in austere or disaster settings where component separation is impractical.^[188]^[189] The low antibody titers empirically reduce passive hemolysis risk from donor plasma in non-group O recipients, with reaction rates under 1% in observational data from trauma cohorts.^[190] Post-typing, transfusions switch to ABO/RhD-compatible products to optimize compatibility and inventory use, as uncrossmatched O dosing beyond initial units elevates wastage without proportional safety gains.^[183] Such scenarios occur infrequently—estimated at 3-6% of emergency department admissions with massive hemorrhage—but prove critical in mass casualty events or remote care, where delays exceed 10-15 minutes for standard serologic typing.^[187] Recent point-of-care advances, including portable agglutination kits and lab-on-chip devices, enable ABO/RhD determination in under 5 minutes via microfluidic hemagglutination detection, bypassing lab centrifugation.^[191]^[192] Emerging portable genotyping platforms, leveraging nanopore sequencing or freeze-dried PCR for ABO loci, further compress times to 3-5 minutes even in field conditions, enhancing accuracy over phenotypic tests in variant cases like weak D phenotypes.^[193]^[194] These tools causally prioritize speed by directly querying genomic antigens, reducing empirical O-negative reliance while maintaining near-zero initial incompatibility risks.^[91]

Religious and Personal Objections

Jehovah's Witnesses refuse transfusions of whole blood and its four primary components—red cells, white cells, platelets, and plasma—interpreting biblical commands in Acts 15:28-29 and Leviticus 17:10-14 as prohibiting the ingestion or use of blood in any form, viewing it as a religious mandate rather than a medical decision.^[195] ^[196] This stance, formalized since the 1940s, extends to autologous blood storage only under specific conditions that avoid violating the no-blood principle, while permitting non-blood volume expanders, erythropoietin, and surgical techniques like cell salvage.^[197] Bloodless medicine programs, developed to accommodate such refusals, have achieved success rates comparable to standard transfusion protocols in elective surgeries. A 2012 study of cardiac surgery patients found Jehovah's Witnesses refusing transfusions experienced fewer acute complications, shorter hospital stays, and similar long-term survival compared to matched patients receiving transfusions.^[198] Similarly, a 2022 analysis of adult inpatients reported equivalent clinical outcomes, including mortality and readmission rates, for those undergoing bloodless care versus standard care, with potential cost savings from reduced transfusion-related risks.^[199] In cardiac procedures specifically, bloodless approaches in Jehovah's Witnesses yielded no significant differences in operative mortality or major morbidity versus non-Witnesses, supporting viability through preoperative optimization, intraoperative hemostasis, and postoperative management.^[200] U.S. courts have consistently upheld competent adults' rights to refuse blood transfusions on religious grounds, affirming autonomy under the First Amendment's free exercise clause. In In re Estate of Brooks (1980), the Illinois Supreme Court ruled that an adult's refusal of life-saving transfusions based on religious beliefs must be honored absent evidence of incompetence.^[201] Similarly, in In re E.G. (1989), the court extended protections to a competent adult with religious objections, emphasizing that state interests in preserving life do not override informed refusal unless incapacity is proven.^[201] These precedents trace to earlier cases like Application of President and Directors of Georgetown College (1964), where refusals were sometimes overridden but later refined to prioritize patient consent in non-emergency contexts for adults.^[202] Beyond religious doctrine, personal objections to transfusions often stem from concerns over risks such as transfusion-transmitted infections, immunomodulation, or ethical sourcing, with individuals asserting bodily autonomy against medical paternalism. Competent patients retain the legal right to refuse even in emergencies if advance directives or witnessed statements exist, as affirmed in bioethics guidelines prioritizing informed consent over presumed benefit.^[203] Empirical data reinforces this, showing restrictive or zero-transfusion strategies in aware patients correlate with noninferior outcomes in controlled settings, underscoring that consent-driven avoidance does not inherently elevate mortality when alternatives are employed.^[199] Such refusals highlight causal tensions between intervention defaults and individual agency, with evidence indicating bloodless pathways mitigate risks without compromising survival in elective and select urgent cases.^[198]

Controversies

Debates on Transfusion Necessity and Restrictive Strategies

The debate over the necessity of blood transfusions centers on the balance between potential benefits and risks, with accumulating evidence challenging traditional liberal strategies that transfuse at higher hemoglobin thresholds (typically 9-10 g/dL) in favor of restrictive approaches (7-8 g/dL). The American Association of Blood Banks (AABB) 2023 international guidelines strongly recommend restrictive strategies for most hospitalized adults and children, initiating transfusion only when hemoglobin falls below 7 g/dL, based on randomized controlled trials (RCTs) demonstrating noninferiority to liberal approaches in outcomes like mortality and morbidity.^[25] ^[204] However, guidelines vary by condition; for instance, a 2025 AABB panel conditionally endorsed a liberal threshold below 10 g/dL for acute myocardial infarction (AMI) patients, citing potential reductions in recurrent MI risk despite increased acute lung injury.^[205] ^[206] This variance reflects ongoing contention, as liberal strategies persist in some practices due to historical norms and concerns over undertransfusion in high-risk cases, though proponents of restriction argue that unproven causal benefits from higher thresholds overlook transfusion-associated harms.^[207] RCTs from 2020-2025, including the MINT trial in AMI patients, have reinforced restrictive strategies' efficacy, showing no increase in major cardiovascular events or death compared to liberal transfusion, alongside reduced transfusion volumes (e.g., 3.5 times fewer units in restrictive arms).^[31] ^[208] Liberal approaches correlate with elevated risks of infections, acute lung injury, and prolonged hospital stays, independent of confounders, while failing to demonstrate consistent survival advantages.^[209] ^[206] Economic analyses highlight additional burdens, with each liberal unit costing approximately £121 in processing and administration, exacerbating resource strain without proportional clinical gains.^[210] Critics of liberal transfusion, drawing from meta-analyses, describe overtransfusion as a "silent epidemic" driven by defensive medicine—fears of liability for anemia-related complications—rather than empirical necessity, urging first-principles reevaluation of oxygen delivery thresholds.^[211] Nationwide trends underscore these shifts: U.S. red blood cell transfusion rates declined significantly from 2011 to 2014 across most disease categories, extending through 2018, without corresponding rises in adverse patient outcomes, suggesting many prior transfusions were unnecessary.^[212] ^[213] This empirical pattern aligns with patient blood management initiatives promoting restrictive protocols, which have halved morbidity in some cohorts while curbing costs and inventory demands.^[209] Persistent liberal holdouts, particularly in conservative clinical settings wary of trial applicability to sicker patients, highlight tensions between evidence-based restraint and precautionary transfusion, though data indicate no broad causal harm from restriction in stable cases.^[214]

Ethical Concerns in Blood Sourcing and Directed Donations

Paid blood donation systems, prevalent in the United States for plasma collection where donors can receive up to $200 per session and donate twice weekly, raise ethical concerns about exploitation of low-income individuals who comprise a disproportionate share of donors.^[215]^[216] While empirical data indicate that rigorous screening achieves safety equivalence between paid and voluntary unpaid donations, with no significant difference in transfusion-transmitted infection rates when protocols are followed, paid systems may crowd out altruistic volunteers by shifting motivations from solidarity to financial gain, potentially reducing overall supply stability.^[217]^[218] The World Health Organization advocates voluntary non-remunerated donations to minimize risks from incentivized high-frequency giving, which in the U.S. allows up to 104 plasma donations annually—far exceeding limits in most countries—and correlates with donor health strains like dehydration and vein damage.^[218]^[219] Directed donations, where blood is sourced from specified individuals such as family members rather than the general pool, offer no proven safety advantage and introduce logistical risks, including delays in processing and transfusion that can endanger patients in urgent scenarios.^[220]^[221] Studies demonstrate higher infectious disease transmission potential from directed units due to donors often being first-time or infrequent participants, who face social pressures that compromise honest health disclosures during screening.^[220]^[222] The U.S. Food and Drug Administration advises against non-medically indicated directed donations, citing evidence that the community supply, drawn from repeat altruistic donors, yields lower-risk products through anonymous, standardized testing.^[220] In 2025, requests for blood from unvaccinated donors against COVID-19 mRNA vaccines have intensified ethical debates, driven by unsubstantiated fears of vaccine component transmission despite no empirical evidence of mRNA persistence beyond 30 days post-vaccination or any associated transfusion risks.^[223]^[224]^[225] Such demands, often framed as patient autonomy imperatives, strain limited supplies—exacerbating shortages in regions reliant on voluntary pools—while experts argue they perpetuate misconceptions and could normalize discriminatory donor selection without causal benefits to outcomes.^[226] Hospitals navigating informed consent must balance these requests against evidence that vaccinated donor blood poses no differential hazard, as mRNA vaccines neither alter DNA nor transmit via transfusion, per longitudinal studies and regulatory consensus.^[224]^[227] Commercial plasma markets amplify access costs, potentially inflating transfusion thresholds, though data affirm screening efficacy over donor origin in ensuring product integrity.^[228] Jehovah's Witnesses represent the primary religious group objecting to blood transfusions, interpreting biblical passages such as Acts 15:28-29 as prohibiting the ingestion of blood in any form, including via transfusion.^[229] This stance extends to whole blood and major components like red blood cells, white blood cells, platelets, and plasma, which are viewed as equivalent to consuming blood.^[230] However, certain blood fractions—such as albumin, immunoglobulins, and clotting factors—are permitted on a conscience basis, as they are derived from pooled plasma and considered not the sacred "life" of blood itself, though this distinction has sparked internal debates and doctrinal clarifications over time.^[229] In cases involving competent adults, U.S. courts have upheld the right to refuse transfusions, prioritizing religious autonomy under the First Amendment and common law principles of informed refusal, provided the patient demonstrates understanding of the consequences.^[201] State intervention is rare for adults, occurring only in scenarios of incompetence or imminent irreversible harm where no advance directive exists, as affirmed in rulings emphasizing that forced treatment violates bodily integrity absent compelling state interest.^[230] For minors, however, courts frequently override parental refusals, appointing temporary guardians to authorize transfusions when life is at stake; notable 1980s examples include Florida cases where Jehovah's Witness parents lost custody battles over pediatric leukemia treatments requiring blood products, balancing parens patriae doctrine against free exercise claims.^[231] Such interventions reflect judicial recognition that children's welfare supersedes parental religious rights when survival is probable with transfusion, though post-1990s competency assessments for mature minors have occasionally deferred to adolescent refusals if deemed sufficiently informed.^[232] Informed consent protocols mandate disclosure of transfusion risks, including hemolytic reactions (1 in 76,000 units), transfusion-related acute lung injury (1 in 5,000), and infectious transmission (e.g., HIV at 1 in 1.5 million), alongside alternatives like blood conservation techniques and hemoglobin-based oxygen carriers.^[233] Empirical data from bloodless programs demonstrate viable outcomes without transfusions, with one risk-adjusted study of over 1,000 patients showing 0.7% mortality in the bloodless cohort versus 2.7% in transfused controls, attributed to reduced infections and optimized preoperative hemoglobin.^[234] Facilities like UF Health employ adjuncts such as Hemopure—a bovine hemoglobin solution—for Jehovah's Witness patients, enabling procedures with survival rates comparable to standard care while respecting refusals.^[235] These findings underscore that transfusion is not invariably lifesaving, supporting autonomy in refusals where bloodless strategies yield equivalent or superior results, challenging absolutist medical imperatives.^[199]

Alternatives and Ongoing Research

Patient Blood Management Techniques

Patient Blood Management (PBM) comprises evidence-based strategies aimed at optimizing a patient's own blood resources to minimize reliance on allogeneic transfusions, thereby reducing associated risks such as infections, transfusion reactions, and prolonged hospital stays. Structured around three pillars—preoperative anemia detection and correction, perioperative blood loss minimization, and rational transfusion decision-making—PBM implementation in surgical programs has demonstrated reductions in red blood cell transfusion rates by 14 to 50 percent across various studies, with corresponding decreases in postoperative complications.^[236]^[237] These approaches prioritize patient-centered care, focusing on physiological tolerance to anemia rather than routine transfusion. The first pillar emphasizes early screening and treatment of preoperative anemia, which affects up to 40 percent of elective surgery patients and independently predicts transfusion needs. Intravenous iron supplementation corrects iron deficiency effectively, reducing the proportion of patients requiring transfusions by 16 percent in major elective procedures, outperforming oral iron due to faster absorption and fewer gastrointestinal side effects.^[238] Adjunctive erythropoietin (EPO) therapy, particularly when combined with iron in non-cardiac surgery, further decreases postoperative anemia incidence and transfusion rates by stimulating endogenous red cell production, with meta-analyses confirming its efficacy in optimizing hemoglobin levels preoperatively.^[239]^[240] Minimizing blood loss forms the second pillar, incorporating intraoperative techniques such as cell salvage and pharmacological hemostasis. Cell salvage involves aspirating, washing, and reinfusing autologous red cells lost during surgery, proven safe and effective in reducing allogeneic transfusion requirements by recovering viable erythrocytes in procedures like orthopedic and cardiac operations, with no increase in adverse events like embolism.^[241] Antifibrinolytic agents, notably tranexamic acid (TXA), inhibit fibrinolysis to curb bleeding; the CRASH-2 trial (202,211 patients, 2010) showed early TXA administration in trauma patients with significant hemorrhage reduced transfusion needs by one-third and all-cause mortality by 1.5 percent without elevating vascular occlusion risks.60835-5/fulltext) In elective surgery, meta-analyses of antifibrinolytics confirm lowered blood loss and transfusion volumes across agent types, with no adverse impact on mortality or morbidity.^[242] The third pillar promotes rational transfusion through restrictive hemoglobin thresholds, typically 7 g/dL in hemodynamically stable adults, versus liberal approaches (e.g., 9-10 g/dL). Large randomized trials, including those in acute myocardial infarction (REALITY trial, 2023) and myocardial injury (MINT trial, 2024), establish restrictive strategies as noninferior for major cardiovascular events and 30-day mortality, achieving 40-50 percent fewer transfusions while avoiding harm in most populations.^[243]^[244] This shift aligns with physiological evidence that tissue oxygenation persists adequately above critical anemia thresholds in non-bleeding patients. In resource-limited settings, 2025 World Health Organization guidance advocates phased PBM adoption, prioritizing low-cost interventions like anemia screening and TXA use to enhance outcomes where blood supply chains falter, demonstrating feasibility through scalable protocols that cut transfusion dependence without advanced infrastructure.^[245] Overall, PBM's multimodal application in elective surgery maintains or lowers mortality compared to transfusion-heavy practices, underscoring its role in evidence-driven conservation.^[246]

Artificial Blood Substitutes and Oxygen Carriers

Hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon (PFC)-based emulsions represent the primary classes of artificial blood substitutes developed to deliver oxygen to tissues independently of donor red blood cells. HBOCs utilize modified hemoglobin molecules, often derived from bovine or human sources, to bind and release oxygen, while PFCs physically dissolve respiratory gases for short-term transport. These agents offer advantages such as universal compatibility, extended shelf life without refrigeration, and no need for blood typing, making them appealing for trauma or remote settings. However, clinical translation has been limited by adverse effects observed in trials.^[247] HBOCs like HBOC-201 (Hemopure), a polymerized bovine hemoglobin solution developed in the 1990s, have undergone extensive testing but faced regulatory hurdles outside limited approvals. Hemopure received approval in South Africa in 2001 for treating acute anemia in elective surgery when blood is unavailable, based on phase III trials showing reduced transfusion needs but no overall survival benefit. In contrast, U.S. and European regulators halted further approvals after trials revealed elevated risks; for instance, a phase III aortic surgery study reported 13% mortality in the HBOC-201 group versus 10% in controls, failing noninferiority endpoints. Bovine-derived HBOCs like Hemopure have demonstrated increased vascular resistance and reduced cardiac output in cardiac surgery patients at doses of 55–97 g hemoglobin.^[248]^[249]^[250] Empirical data from meta-analyses underscore HBOC toxicities, including a 2008 pooled analysis of 16 trials across five products indicating a 30% relative increase in mortality and 2.7-fold higher myocardial infarction risk compared to controls. More recent reviews confirm these findings, attributing harms to mechanisms such as nitric oxide scavenging, which induces vasoconstriction, hypertension, and endothelial dysfunction; heme-mediated oxidative stress damaging cardiomyocytes; and procoagulant effects elevating thrombosis risk. A 2021 meta-analysis of 13 randomized trials similarly linked HBOC use to significantly higher mortality. These causal pathways explain why first-generation HBOCs failed safety thresholds in broad populations, despite oxygen-carrying efficacy.^[251]^[252]^[249] PFC emulsions, such as perfluorodecalin-based formulations, provide temporary oxygen delivery by high solubility for O2 and CO2 but require supplemental hyperoxia for efficacy and exhibit short plasma half-lives, limiting them to bridge therapies rather than full substitutes. As of 2024, PFCs remain largely experimental, with albumin-derived variants in early development for red blood cell alternatives, though clinical trials highlight challenges like reticuloendothelial sequestration and potential immunogenicity. No PFC product has achieved widespread approval for transfusion-like use, due to insufficient duration and dependency on ventilatory support.^[253]^[254] Military interest persists in HBOCs for battlefield logistics, exemplified by the U.S. Defense Advanced Research Projects Agency's 2023–2024 allocation of $46.4 million to advance polymerized hemoglobin products like ErythroMer, aiming for hemorrhage control in austere environments. Proponents cite potential in oxygen debt reversal where blood is scarce, yet civilian analyses emphasize unmitigated risks in non-hypoxic patients, with meta-analytic evidence of net harm overriding theoretical benefits. Ongoing research focuses on encapsulation or genetic modifications to curb vasoconstrictive effects, but as of 2025, no HBOC or PFC has demonstrated safety superior to conservative transfusion strategies in randomized data.^[255]^[256]

Emerging Cellular and Synthetic Approaches

Induced pluripotent stem cells (iPSCs) derived from somatic cells can be differentiated into enucleated erythrocytes capable of oxygen transport, providing a renewable source independent of blood donors.^[257] Preclinical studies have demonstrated that these lab-cultured red blood cells (RBCs) exhibit functional maturity, including hemoglobin expression and deformability akin to donor-derived cells, though with variable enucleation rates below 50% in many protocols. A phase I clinical trial initiated in 2023-2024 evaluates the circulation half-life of transfusion-grade iPSC-derived RBCs in healthy volunteers, marking the first human assessment of such cells' post-infusion survival, which preliminary data suggest persists for up to 100 days in small cohorts but requires optimization for therapeutic dosing.^[258] To enhance compatibility, enzymatic conversion techniques use bacterial α-galactosidases and α-N-acetylgalactosaminidases to remove A and B antigens from group A, B, or AB RBCs—whether donor-sourced or lab-grown—yielding type O cells by exposing the underlying H antigen.^[259] This process achieves over 90% antigen removal in vitro, reducing hemagglutination risks, though residual epitopes can persist and necessitate Rh compatibility checks for full O-negative equivalence.^[260] For Rh-negative universality, separate strategies target D antigen removal, but enzymatic methods alone do not alter Rh proteins, limiting them to ABO modifications.^[261] CRISPR/Cas9 gene editing addresses both ABO and Rh barriers by knocking out specific loci in iPSC lines, such as ABO for type O conversion or RHD/RHCE for Rh-null phenotypes lacking all Rh antigens.^[262] In Rh-null hiPSC models, dual-guide RNA edits converted type A cells to O-negative equivalents, with edited erythrocytes showing no antigen expression and normal erythropoiesis upon differentiation.^[263] Combinatorial editing for multiple antigens has produced customizable RBCs compatible with rare recipient types, bypassing alloimmunization from mismatched transfusions.^[264] Scalability challenges persist, as iPSC expansion yields only 10^8-10^9 functional RBCs per bioreactor run—far short of the 2x10^11 cells needed for one adult transfusion unit—due to inefficiencies in maturation, enucleation, and bioreactor design.^[265] Production costs exceed $10,000 per unit in 2024 estimates, driven by cytokine requirements and quality control, rendering routine clinical use uneconomical without bioreactor advancements. While these approaches causally eliminate donor variability and pathogen risks, long-term in vivo data on edited cells' stability and immunogenicity remain absent, with preclinical models indicating potential for off-target edits or altered vascular interactions.^[266] Ongoing 2025 refinements focus on immortalized erythroid progenitors to boost yields, positioning cellular methods as a futuristic complement to traditional transfusions amid chronic shortages.^[267]

Veterinary Use

Blood transfusions in veterinary medicine are employed to manage conditions such as acute hemorrhage, severe anemia, coagulopathies, and hypoproteinemia in various species, including dogs, cats, horses, and exotic animals. The procedure involves administering whole blood, packed red blood cells, fresh frozen plasma, or cryoprecipitate, with indications primarily centered on restoring oxygen-carrying capacity or clotting factors. In small animal practice, transfusions are most commonly performed in emergency settings for trauma, surgical blood loss, or toxicities like anticoagulant rodenticide ingestion.^[268]^[269]^[270] The historical origins trace to 1665, when English physician Richard Lower conducted the first documented successful transfusion between dogs, using a quill and artery-to-vein connection to demonstrate blood's role in sustaining life. Veterinary applications evolved alongside human medicine, with early 20th-century advancements in anticoagulants enabling safer canine and equine transfusions; by the mid-20th century, blood typing systems like canine DEA 1.1 and feline AB groups were identified to mitigate incompatibility risks. Modern protocols emphasize donor screening for health and blood type compatibility, with cross-matching recommended prior to repeat transfusions to prevent hemolytic reactions.^[271]^[272]^[273] Administration guidelines vary by species and product: for dogs, packed red blood cells are dosed at 6-10 ml/kg over 2-4 hours to achieve a hematocrit increase of 10-20%, starting slowly at 1-2 ml/min to monitor for reactions; cats require type B donors for type A recipients due to naturally occurring anti-B antibodies, with volumes limited to 10-15 ml/kg. Horses and large animals often receive whole blood via jugular venipuncture for conditions like exercise-induced anemia or colic-related hemorrhage. Transfusion rates are adjusted for patient size, with warming to body temperature to avoid hypothermia.^[268]^[274]^[275] Complications, though less frequent than in humans due to species-specific adaptations, include acute hemolytic reactions from ABO-incompatible feline transfusions (potentially fatal within minutes), allergic responses manifesting as urticaria or vomiting, and non-immunologic issues like circulatory overload or bacterial contamination from poor donor hygiene. Incidence of severe reactions is estimated at 1-5% in typed, cross-matched transfusions, underscoring the need for vigilant monitoring including vital signs every 15-30 minutes during administration. Evidence from veterinary referral centers indicates that pre-transfusion compatibility testing reduces reaction rates significantly compared to untyped whole blood use.^[276]^[277]^[278]

References

[1]
Blood Transfusion - StatPearls - NCBI Bookshelf
Jun 20, 2023 · Blood transfusions are a relatively common medical procedure, and while typically safe, there are multiple complications that practitioners need to be able to ...
[2]
NCD - Blood Transfusions (110.7) - CMS
Blood transfusions are used to restore blood volume after hemorrhage, to improve the oxygen carrying capacity of blood in severe anemia, and to combat shock.
[3]
Treatments for Blood Disorders - NHLBI
Mar 24, 2022 · Blood transfusions replace blood that is lost through surgery or injury. This treatment also provides blood if your body is not making blood ...
[4]
Milestones in Transfusion Medicine - Hematology.org
1818, The first successful human-to-human blood transfusion is performed by James Blundell. ; 1900, Karl Landsteiner develops the classification of blood into A, ...
[5]
Transfusion Risks and Transfusion-related Pro-inflammatory ...
It, however, can lead to sepsis in 17% to 25% of patients transfused with contaminated blood, with an associated mortality rate of 26% [1]. Additionally, it ...
[6]
Blood Transfusion Reactions—A Comprehensive Review of ... - MDPI
May 19, 2022 · We aim to provide a structured overview of the pathophysiology, clinical presentation, diagnostic approach and management of acute transfusion reactions
[7]
Clinical evidence of blood transfusion effectiveness - PMC
The present article reviews: (i) physiological principles of oxygen transport, including compensatory mechanisms of acute anaemia and limits of anaemia ...
[8]
Transfusion of Blood and Blood Products - PMC - PubMed Central
RBC transfusions are mainly administered to improve tissue oxygenation in cases of anaemia or acute blood loss due to trauma or surgery.
[9]
ABO Blood Group System - StatPearls - NCBI Bookshelf
Apr 26, 2025 · Special attention is given to the risks of ABO incompatibility, including hemolytic transfusion reactions and hemolytic disease of the newborn, ...Missing: empirical data
[10]
Blood Transfusion Reactions—A Comprehensive Review of the ...
May 19, 2022 · Immune-mediated acute hemolytic transfusion reactions (AHTR) are most often related to ABO incompatibility but can also be caused by non-ABO ...
[11]
Time to revisit red blood cell additive solutions and storage conditions
Several countries apply a shorter 5 weeks shelf-life to their SAGM-RBC components despite the fact that SAGM is approved for 6 weeks storage. SAGM has not been ...
[12]
Red Blood Cell Products for Medical Needs | American Red Cross
The shelf life of RBCs is determined by the anticoagulant and additive solution. AS-1, AS-3, and AS-5 have a 42-day shelf life. RBCs can also be treated ...Missing: FDA | Show results with:FDA
[13]
Stored blood: how old is too old? - JCI
Dec 12, 2016 · The FDA requires that rbc units show less than 1 % hemolysis at the end of storage and that the average 24-hour posttransfusion recovery of ...
[14]
Supercooled storage of red blood cells slows down the metabolic ...
Oct 3, 2025 · Today, packed RBC units are stored under refrigerated conditions (+4 °C, a.k.a. cold storage) for up to 42 days in the United States.
[15]
Plasma, Platelets and Whole Blood | Red Cross Blood Services
The transfusable components that can be derived from donated blood are red cells, platelets, plasma, cryoprecipitated AHF (cryo), and granulocytes.
[16]
Platelet product quality remains high after seven days of storage
The improved bacterial testing procedures that allow a seven-day shelf life are expected to increase the safety of platelet products, relieve inventory pressure ...
[17]
Platelet storage duration and its clinical and transfusion outcomes
Aug 5, 2018 · Platelets (PLTs) are usually stored for up to 5 days prior to transfusion, although in some blood services the storage period is extended to ...
[18]
Fresh Frozen Plasma (FFP): What It Is & Uses - Cleveland Clinic
Within eight hours of collecting it, they freeze it at -18 degrees Celsius or lower until it's ready to use. This is why it's called fresh frozen plasma. Other ...
[19]
Plasma products for transfusion: an overview - Annals of Blood
Mar 31, 2022 · After freezing, FFP can be stored for up to 1 year at ≤−18 ℃, or with special FDA approval, for up to 7 years at −65 ℃ (3). At the time of use, ...
[20]
Cryoprecipitated AHF (Cryo) - Red Cross Blood Donation
Cryo contains fibrinogen, Factor VIII, Factor XIII, von Willebrand Factor (vWF), and fibronectin. · Cryo is prepared by thawing one (1) unit of plasma at 1–6°C ...
[21]
The Secrets of Cryoprecipitate: A Blood Banking Process - Insights
Oct 7, 2019 · Cryoprecipitate is stored at negative 18°C or colder, and has a shelf life of 1 year. For pooled cryo, the expiration date is determined to be ...Missing: composition | Show results with:composition
[22]
The Use of Whole Blood Transfusion in Trauma - PMC - NIH
Jan 17, 2022 · The use of Whole Blood has increased in the civilian trauma population and there is a growing body of evidence to support its current use. More ...
[23]
The Role of Whole Blood Transfusions in Civilian Trauma
Apr 18, 2022 · The authors conclude that whole blood may be the superior product for adult trauma patients compared to component transfusions, with potential ...
[24]
Red Blood Cell Transfusion: 2023 AABB International Guidelines
Oct 12, 2023 · The most common liberal transfusion threshold was 9 to 10 g/dL and the most common restrictive threshold was 7 to 8 g/dL. Table 2 presents the ...
[25]
Red Blood Cell Transfusion: 2023 AABB International Guidelines
Nov 21, 2023 · In accordance with the restrictive strategy threshold used in most trials, clinicians may choose a threshold of 7.5 g/dL for patients undergoing ...
[26]
Transfusion Strategies for Acute Upper Gastrointestinal Bleeding
Jan 3, 2013 · Transfusion may be lifesaving in patients with massive exsanguinating bleeding. However, in most cases hemorrhage is not so severe, and in such ...
[27]
Transfusion of Blood and Blood Products: Indications and ... - AAFP
Mar 15, 2011 · Indications for RBC transfusion include acute sickle cell crisis (for stroke prevention), or acute blood loss of greater than 1,500 mL or 30 ...Abstract · Red Blood Cells · Platelets · Acute Transfusion Reactions
[28]
Indications and hemoglobin thresholds for RBC transfusion in adults
Jul 24, 2024 · Trauma/massive transfusion · Intensive care unit · Septic shock · Acute bleeding · Orthopedic surgery · Chronic kidney disease · Chronic ...
[29]
Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery
Nov 12, 2017 · The TRICS III trial provides compelling evidence that a restrictive transfusion strategy is as effective and safe as a liberal strategy in ...
[30]
Liberal or Restrictive Transfusion in High-Risk Patients after Hip ...
Dec 14, 2011 · We performed the Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS) to ...
[31]
Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major ...
Feb 9, 2021 · This noninferiority trial compares the effects of a restrictive (hemoglobin ≤8 g/dL) vs liberal (hemoglobin ≤10 g/dL) transfusion strategy ...
[32]
Platelet Transfusion: A Clinical Practice Guideline From the AABB
The AABB recommends transfusing hospitalized adult patients with a platelet count of 10 × 10 9 cells/L or less to reduce the risk for spontaneous bleeding.
[33]
AABB Develops New Platelet Transfusion Guidelines
May 29, 2025 · In patients undergoing lumbar puncture, platelet transfusion is recommended when platelet count is less than 20x103/µL.
[34]
Platelet Transfusion - StatPearls - NCBI Bookshelf
Jun 6, 2024 · The treatment is indicated in the following bleeding cases: Less than 50,000 cells/μL with severe bleeding, including disseminated ...Continuing Education Activity · Indications · Preparation · Complications
[35]
Fresh Frozen Plasma: thresholds and targets - Blood Transfusion
Only consider fresh frozen plasma transfusion for patients with clinically significant bleeding but without major haemorrhage if they have abnormal coagulation ...
[36]
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a ...
Feb 3, 2015 · A pragmatic, phase 3, multisite, randomized trial, the PROPPR study compared the effectiveness and safety of a 1:1:1 transfusion ratio of plasma ...
[37]
Transfusion of Fresh Frozen Plasma and Platelets in Critically Ill Adults
Mar 10, 2025 · The leading indications include mild abnormalities in platelet counts and coagulation tests in non-bleeding patients and procedural prophylaxis.
[38]
Use of fresh frozen plasma (FFP) | Australian Red Cross Lifeblood
Fresh frozen plasma (FFP) is used for patients with one or more coagulation factor deficiencies who are bleeding or at risk of bleeding.
[39]
Massive Transfusion - StatPearls - NCBI Bookshelf
Sep 15, 2025 · A massive transfusion involves the administration of 10 units or more of whole blood or packed red blood cells (PRBCs) within 24 hours.
[40]
Massive transfusion and massive transfusion protocol - PMC
DEFINITION OF MASSIVE BLOOD TRANSFUSION · Replacement of one entire blood volume within 24 h · Transfusion of >10 units of packed red blood cells (PRBCs) in 24 h.
[41]
Transfusion of plasma, platelets, and red blood cells in a 1 ... - PubMed
Feb 3, 2015 · Objective: To determine the effectiveness and safety of transfusing patients with severe trauma and major bleeding using plasma, platelets, and ...Missing: efficacy | Show results with:efficacy
[42]
Viscoelastic Hemostatic Assays are Associated With Mortality ... - NIH
Jan 24, 2025 · A viscoelastic hemostatic assay-based TIC score is independently associated with mortality and pRBC transfusion volumes.
[43]
Timing to First Whole Blood Transfusion and Survival After Severe ...
Jan 31, 2024 · This cohort study examines whether the timing of whole blood transfusion is associated with improved survival among adult trauma patients ...
[44]
Improving Access to Prehospital Blood May Save 10000 Lives a Year
Mar 5, 2025 · A 2024 cohort study in JAMA Surgery found that transfusion of whole blood was associated with a 60% decrease in mortality at 24 hours in ...
[45]
Mortality in Critically Ill Patients with Liberal Versus Restrictive ...
Mar 18, 2025 · Our meta-analysis found no statistically significant difference in the short-term mortality between restrictive and liberal transfusion strategies.
[46]
Transfusion thresholds for guiding red blood cell transfusion - 2021
Dec 21, 2021 · The restrictive transfusion threshold uses a lower haemoglobin concentration as a threshold for transfusion (most commonly, 7.0 g/dL to 8.0 g/dL).<|separator|>
[47]
Recommendations on Red Blood Cell Transfusion in General ...
The TRIPICU study showed no difference in outcomes between transfused and non-transfused stable PICU patients with Hb level above 7 g/dL. A similar outcome has ...
[48]
Clinical outcomes of restrictive versus liberal blood transfusion ...
Findings from this meta-analysis show that restrictive strategies significantly reduce nosocomial infections in children.
[49]
Risks of Restrictive Versus Liberal Red Blood Cell Transfusion ...
May 15, 2024 · The restrictive trigger threshold was associated with an increased combined risk of myocardial infarction and death as compared with hemoglobin ...
[50]
Liberal vs Restrictive Hemoglobin Levels as Thresholds for Blood ...
The authors found no difference in 30-day mortality between liberal and restrictive transfusion protocols (Relative risk [RR] 0.97, 95% CI 0.8 to 1.2). However, ...
[51]
Randomized Trial of Transfusion Strategies in Patients With ...
May 16, 2021 · The results of this trial indicate that a restrictive PRBC transfusion strategy (transfusion for Hgb ≤8 g/dl, goal 8-10 g/dl) is noninferior to ...
[52]
Red Blood Cell Transfusion in Critically Ill Adults - Chest Journal
Sep 26, 2024 · The primary indication is low hemoglobin (80%), whereas less frequently encountered indications include active bleeding (27%) and hemodynamic ...Missing: loss | Show results with:loss
[53]
SHOT Report: Transfusion-Related Mortality in the UK Increased in ...
Jul 23, 2025 · Delays increased by 47.2%, from 212 in 2023 to 312 in 2024, and avoidable transfusions increased by 33.9%, from 127 in 2023 to 170 in 2024. In ...
[54]
Effects of restrictive red blood cell transfusion on the prognoses of ...
May 31, 2018 · Recent studies have demonstrated that a restrictive strategy for RBC transfusion is not inferior to a liberal strategy with respect to death and ...
[55]
World Blood Donor Day – Altruism and Safer Blood
Jun 13, 2018 · Donors who give blood for altruistic reasons rather than for compensation or for a family member in an emergency are more likely to be healthy ...Missing: models empirical
[56]
Blood donors' attitudes towards incentives: influence on motivation ...
The RetroEpidemiology Donor Study (REDS) showed that donors who reported being encouraged to donate due to incentives were 1.6 times more likely to be at risk ...
[57]
Donor selection, donor testing and pathogen reduction
Aug 13, 2021 · The time for phlebotomy varies from 10 to 15 minutes. Approximately 480 ml of blood are collected per donation. The first few millilitres of ...
[58]
5.7: Whole blood donation - JPAC
Sep 4, 2023 · The donor should be asked to open and close his/her hand slowly every 10–12 seconds to encourage a free flow of blood.
[59]
Apheresis: How It Works - Cleveland Clinic
In apheresis, a centrifuge machine removes blood from your body. You may participate in apheresis so you can donate blood elements to help others.Missing: phlebotomy | Show results with:phlebotomy
[60]
Blood donation - Mayo Clinic
Nov 30, 2023 · During apheresis, you are hooked up to a machine that can collect and separate different parts of your blood, such as red cells, plasma and ...Missing: phlebotomy | Show results with:phlebotomy
[61]
[PDF] Common Donor Deferrals - AABB
Common deferrals include certain medications, cancer/bleeding history, certain vaccinations, travel to endemic areas, and certain sexual activity.Missing: screening | Show results with:screening
[62]
Donor Safety, Screening and Testing - AABB
All donors must read the Blood Donor Educational Material and use the Medication Deferral List to complete the DHQ as part of this FDA recognized system. The ...
[63]
21 CFR 630.10 -- General donor eligibility requirements. - eCFR
(A) Female allogeneic donors must have a hemoglobin level that is equal to or greater than 12.5 grams of hemoglobin per deciliter of blood, or a hematocrit ...
[64]
Hemoglobin Screening/Iron Management - AABB
Minimum hemoglobin for male donors is 13.0 g/dL, and for female donors, it's 12.5 g/dL, though 12.0-12.5 g/dL is allowed with additional steps.
[65]
Iron Deficiency and Blood Donation: Links, Risks and Management
Dec 10, 2022 · Iron deficiency without anemia (IDWA) and iron deficiency anemia (IDA) are common consequences of regular blood donation.
[66]
Iron Status of Blood Donors - PMC
Nov 1, 2023 · This review examines recent research on the prevalence and importance of iron deficiency in blood donors, and on efforts to mitigate it.
[67]
[PDF] Updated Strategies to Limit or Prevent Iron Deficiency in Blood Donors
Mar 16, 2017 · 1 Mounting evidence indicates that frequent donors require iron supplementation to prevent significant iron depletion that may have deleterious ...
[68]
The ethics of blood donation: Does altruism suffice? - ScienceDirect
Firstly, as regards safety and supply, there has been no evidence that paid donations have helped ensure the sustainability of a safe and adequate blood supply ...
[69]
https://www.redcross.org/about-us/news-and-events/press-release/2024/red-cross-declares-emergency-blood-shortage-calls-for-donations-during-national-blood-donor-month.html
[70]
Red Cross, America's Blood Centers, AABB Say U.S. Faces Critical ...
Aug 7, 2024 · The American Red Cross said it faces an emergency blood shortage after its national blood inventory plummeted more than 25% in July.Missing: increases | Show results with:increases
[71]
https://slate.com/technology/2025/10/blood-donation-hospitals-red-cross-plasma-bank.html
[72]
[PDF] Reveos® Automated Whole Blood Processing System ... - FDA
Jun 23, 2023 · The Reveos System uses centrifugal force to separate one to four units of whole blood into constituent components (plasma, platelets, red blood ...
[73]
[PDF] Guidance for Industry: Pre-Storage Leukocyte Reduction of Whole ...
Automated Blood Cell Separator (ABCS): A device that uses a centrifugal or filtration separation principle to automatically withdraw Whole Blood from a donor, ...
[74]
Significance of Adopting Nucleic Acid Amplification Technique ... - NIH
Oct 27, 2021 · Nucleic acid Amplification testing (NAT) has helped improve blood safety and detect window period and Occult Hepatitis B infections (OBI).
[75]
[PDF] Use of Nucleic Acid Tests on Pooled and Individual Samples ... - FDA
Depending on the sensitivity of the test, implementation of HBV NAT has the potential to reduce risk of infection to levels similar to those for HIV and HCV.
[76]
[PDF] Bacterial Risk Control Strategies for Blood Collection ... - FDA
Blood collection establishments and transfusion services should establish procedures to assure traceability of the bacterial testing status of platelet products.
[77]
Clinical Guidance for Bacterial Contamination and Blood Safety - CDC
Feb 14, 2024 · Bacterial contamination of platelet components is the second most common cause of transfusion-related infection deaths in the United States.
[78]
Platelet PGD Test - Verax Biomedical
Use of the PGD test within 24 hours of transfusion offers the opportunity to interdict and prevent the transfusion of a proportion of severely contaminated ...
[79]
Platelet preservation: agitation and containers - PubMed
For platelets to maintain their in vitro quality and in vivo effectiveness, they need to be stored at room temperature with gentle agitation in gas-permeable ...
[80]
[PDF] 7.4: Platelet Components - JPAC
During transportation the temperature of platelets must be kept as close as possible to the recommended storage temperature and, on receipt, unless intended for ...<|separator|>
[81]
[PDF] AABB 2024 - intercept-usa
Sep 27, 2024 · Evaluation of Pathogen Reduction Efficacy in Platelet Concentrates. Until End of Shelf-Life With Two Different Automated Bacterial. Detection ...
[82]
Bacterial Contamination of Platelet Products - PMC - NIH
Jan 26, 2024 · Three methods for pathogen reduction of platelet concentrates have been developed—INTERCEPT Blood System (Cerus Corporation), Mirasol System ( ...
[83]
Pre-transfusion testing | Professional Education
Jul 13, 2020 · Pre-transfusion tests include ABO and RhD typing of the patient's red blood cells and an antibody screen with the patient's plasma.
[84]
Compatibility Testing in Blood Transfusion: Procedures and Standards
Sep 30, 2025 · Minor crossmatches are no longer required by AABB since 1976 due to advancements in testing methods and understanding of transfusion reactions.
[85]
[PDF] Fundamental Standards for Blood Collection and Transfusion - AABB
Methods of testing shall be those that demonstrate clinically significant ... of blood before completion of compatibility testing or infectious disease ...
[86]
Computer Crossmatch Compatability Donor and Recipient Serum or ...
May 15, 2019 · "Computer crossmatch" is a process used to ensure that blood released for transfusion is compatible with the intended recipient.Missing: criteria | Show results with:criteria
[87]
Computer Crossmatch - Blood Bank Guy Glossary
The computer crossmatch (aka, "electronic crossmatch") is a major crossmatch done without the need for contact between donor red cells and patient serum.
[88]
Massive hemorrhage and emergency transfusion
Sep 7, 2021 · Type O uncrossmatched red blood cells should be used if the patient's blood group is unknown and transfusion is immediately required. In this ...
[89]
Experience with uncrossmatched blood refrigerator in emergency ...
Oct 9, 2018 · Storing uncrossmatched blood in the ED is an effective way to get PRBCs transfused quickly in hemorrhaging patients and is associated with a low rate of ...
[90]
[PDF] GUIDELINES FOR MONITORING TRANSFUSION RECIPIENTS
The patient's vital signs (temperature, pulse, respirations, and blood pressure) should be recorded shortly before transfusion, and after the first 15 minutes ...
[91]
Recent Advances in Point-of-Care Testing Devices for Transfusion ...
Oct 11, 2025 · Various efforts have been made to extend blood grouping, genotyping, and compatibility testing to improve blood transfusion practices, ...
[92]
Improving transfusion medicine in resource-limited settings by point ...
Jun 10, 2025 · This paper presents a portable point-of-care testing (POCT) device to conduct simultaneous and on-site tests of ABO and Rh(D) forward blood ...
[93]
Transfusion Reactions - StatPearls - NCBI Bookshelf
Transfusion reactions are defined as adverse events associated with the transfusion of whole blood or one of its components. These may range in severity ...Missing: principles | Show results with:principles
[94]
Hemolytic Transfusion Reaction - StatPearls - NCBI Bookshelf
Sep 12, 2023 · For acute hemolytic reactions, the usual incompatibility is blood group system ABO. However, there can also be reactions with other "minor ...Continuing Education Activity · Introduction · Etiology · Pathophysiology
[95]
Hemolytic reaction after major and minor compatible blood ...
The acute hemolytic transfusion reaction is a medical emergency with an estimated frequency of one per 70,000 blood product transfusions and an estimated ...
[96]
Noninfectious transfusion-associated adverse events - Annals of Blood
FNHTR is the most common type of transfusion reaction, accounting for 29–55% of the noninfectious adverse events of transfusions and occurring in 1% to 4% of ...
[97]
IgA anaphylactic transfusion reactions - PubMed
IgA anaphylactic transfusion reactions are rare events, estimated to occur in 1 in 20,000 to 47,000 transfusions. The signs and symptoms of these reactions ...
[98]
TRALI | A New Case Definition, a New Epidemic? - ATS Journals
The incidence of TRALI is frequently reported as 1 occurrence for every 5,000 blood component transfusions (2, 3); however, this is thought to be a vast ...Missing: peer | Show results with:peer
[99]
Update on transfusion-related acute lung injury - Frontiers
May 11, 2023 · Although estimates of TRALI mortality vary markedly between 5% and 25% (7, 8), they can reach 47% in intensive care and surgical patients (9).
[100]
Screening of multiparous women to avoid transfusion-related acute ...
The aim of this study was to investigate which approach for serological testing of multiparous donors might be feasible and effective to reduce the risk of ...
[101]
Prevalence, Incidence, and Residual Risk of HIV, HBV, and HCV in ...
Overall incidence and RR estimates for the final 2-year period are shown in the Table; notably, the risk was less than 1 in 5 million for HIV and HCV and ...
[102]
The risk of transfusion-transmitted viral infections ... - PubMed - NIH
Conclusions: The risk of transmitting HIV, HTLV, HCV, or HBV infection by the transfusion of screened blood is very small, and new screening tests will reduce ...
[103]
Does Platelet Transfusion Increase the Risk for Healthcare ...
Mar 25, 2024 · Recent estimates are that clinically significant bacterial contamination occurs in approximately 1 in every 5,000 platelet units and ...<|separator|>
[104]
Pathogen Inactivation Technologies for Cellular Blood Components
Currently, the risk of bacterial contamination, especially in platelet concentrates (1:2,000 to 1:5,000), and transfusion-related bacterial sepsis (1:20,000 to ...
[105]
Assessing the risk of transfusion-transmitted variant Creutzfeldt ... - NIH
Several countries have recently reassessed the international risk of variant Creutzfeldt-Jakob disease (vCJD) transmission through transfusion of blood and ...
[106]
Absence of evidence of transfusion transmission risk of Creutzfeldt ...
Apr 22, 2024 · The study suggests that CJD may not be transfusion-transmissible, a position in agreement with similar findings from two similar European ...
[107]
Prevalence of Transfusion-Transmissible Infections Among ... - NIH
Sep 29, 2024 · Transfusion-transmissible infections (TTIs) pose a significant risk to blood transfusion safety, especially in low-resource settings. TTIs ...
[108]
Prevalence and risk factors evaluation for transfusion-transmissible ...
According to the WHO Global Database on Blood Safety, the prevalence of TTIs in blood donations is considerably lower in high-income countries than in low- and ...
[109]
Infectious Complications of Blood Transfusion - StatPearls - NCBI
Jul 31, 2023 · Infectious complications of blood transfusion, although rare in developed countries, can be life-threatening and lead to significant morbidity and mortality.
[110]
Inflammatory response, immunosuppression, and cancer recurrence ...
An association between perioperative transfusion of allogeneic blood products and risk for recurrence has been shown in colorectal cancer in randomized trials.
[111]
Transfusion related immunomodulation (TRIM) - Pathology Outlines
Apr 10, 2024 · Potential adverse effects related to TRIM include increased risk for infection, organ dysfunction and recurrence or progression of cancer.
[112]
Effect of RBC Transfusion on Oxygenation Status - Oxford Academic
Oct 1, 2021 · Red cells stored in anticoagulant citrate dextrose solution deplete 65% to 85% of their 2,3-DPG content after 14 days of storage.2 Following ...
[113]
Stored blood has compromised oxygen unloading kinetics that can ...
A recent study found that storage paradoxically hastens gas exchange, despite also increasing O2-affinity, and that normalizing [2,3-DPG] has no effect on O2 ...
[114]
Transfusion-associated circulatory overload in adult, medical ...
Transfusion-associated circulatory overload is characterised by acute respiratory distress, tachycardia, increased blood pressure, acute pulmonary oedema ...
[115]
Noninfectious Complications of Blood Transfusion - StatPearls - NCBI
Mar 28, 2025 · Noninfectious complications of blood transfusions range from mild to life-threatening and require prompt recognition and management. Symptoms ...
[116]
Trends in Red Blood Cell, Plasma, and Platelet Transfusions ... - NIH
Feb 27, 2018 · RBC transfusions decreased from 6.8% (95% CI, 6.4%-7.2%) in 2011 to 5.7% (95% CI, 5.6%-5.9%) in 2014 (aRR, 0.83 [95% CI, 0.78-0.88]).
[117]
How Low Should We Go: A Systematic Review and Meta-Analysis of ...
In summary, a restrictive blood transfusion strategy appears to decrease blood utilization in oncology patients without increasing morbidity or mortality. The ...Missing: harm | Show results with:harm
[118]
Blood transfusion is correlated with elevated adult all-cause ... - NIH
May 4, 2024 · Blood transfusion significantly impacts long-term all-cause and cardiovascular mortality and may be an unacknowledged risk factor for death.
[119]
Impact of Blood Product Transfusion on Short and Long-Term ...
The primary result of our study showed that blood transfusion is a great risk factor for early as well as late mortality for at least up to 5 years post cardiac ...
[120]
Effect of blood transfusion on long-term survival after cardiac operation
We found that blood transfusions during or after coronary artery bypass operations were associated with increased long-term mortality.
[121]
THE ASSOCIATION BETWEEN THE TRANSFUSION OF OLDER ...
The amount of older blood transfused is associated with complicated sepsis. While the best strategy to minimize the effects of allogeneic blood is to avoid ...
[122]
Effect of Blood Products Transfusion on the Development of ...
Oct 18, 2010 · Transfusion of fresh frozen plasma (FFP) and platelets is independently associated with the development of multiple organ failure (MOF) in critically injured ...
[123]
Long-term survival after blood transfusion - PubMed
Twenty-four percent of patients died within 1 year after the transfusion, 30 percent within 2 years, 40 percent within 5 years, and 52 percent within 10 years.
[124]
The influence of a simple blood transfusion policy on ... - NIH
Trial data suggests that excessive transfusion may be detrimental, yet overtransfusion remains commonplace. This study reports the impact of introducing a ...
[125]
[PDF] annual shot report 2024 - Serious Hazards of Transfusion
... UK Blood Services record donor complications as per the 'Standard Surveillance of Complications ... 2024 remain consistent with previous Annual SHOT Reports ...
[126]
Impact of intraoperative allogenic and autologous transfusion ... - LWW
Oct 9, 2020 · Intraoperative autologous blood transfusion possessed less impact on immune function, it may even improve immune function and RFS in HCC patients after surgery.
[127]
Allogeneic versus autologous blood transfusion and survival after ...
CONCLUSION: Although allogeneic but not autologous BT was associated with decreased long-term OS, after adjustment for confounding clinical variables, BT was ...
[128]
Transfusion Medicine History - AABB
1818 James Blundell, a British obstetrician, performs the first successful transfusion of human blood to a patient for the treatment of postpartum hemorrhage.
[129]
Jean-Baptiste Denis • LITFL • Medical Eponym Library
First transfusion: On June 15, 1667: Denis performed the first documented human blood transfusion. He transfused twelve ounces of sheep's blood into a 15 ...
[130]
Beast in the Blood: Jean Denis and the “Transfusion Affair”
Mar 22, 2023 · During the late 1660s in Paris, transfusing the blood of calves and lambs into human veins held the promise of renewed youth and vigour.
[131]
Forgotten transfusion history: John Leacock of Barbados - PMC - NIH
James Blundell of London is credited with introducing blood transfusion into the practice of medicine. It was his extensive research in animals and his well ...
[132]
Blood work: A tale of medicine and murder in the scientific revolution
The main thrust of the tragic story is that transfusions were ultimately forbidden for centuries in France because of medical politics, personality clashes, and ...
[133]
Blood Transfusion in the First World War
By 1900, transfusions typically involved connecting blood vessels of donor and recipient using India rubber tubing. A method to suture blood vessels together ...
[134]
a success at age 50; blood banking and sodium citrate
Apr 15, 2008 · Dr Luis Agote used sodium citrate for transfusion of whole blood for a patient on November 9, 1914. ... Instead of publishing his work in a ...
[135]
Blood Transfusion in World War I: The Roles of Lawrence ... - PubMed
Second, US Army Captain Oswald Hope Robertson showed that stored, syphilis-tested, universal donor whole blood could be given quickly and safely in forward ...
[136]
Blood and War - PMC - NIH
Blood transfusion in World War I: The roles of Lawrence Bruce Robertson and Oswald Hope Robertson in the “Most Important Medical Advance of the War”.
[137]
[PDF] Fact Sheet: Blood Plasma - The National WWII Museum
Medics on the battlefield simply reconstituted the dried plasma by adding water before transfusion. wounded during the Blitz.
[138]
Dried Plasma - PMC - NIH
Dried plasma provides an alternative for early plasma transfusion in the resuscitation of hemorrhagic shock in environments where fresh frozen plasma is not ...
[139]
Blood Program in World War II - AMEDD Center of History & Heritage
Fifth U.S. Army. Evolution of Policies Early Experiences First Planning for a Theater Blood Bank Establishment of Blood Bank at 15th Medical General Laboratory
[140]
History of Blood Transfusions - Red Cross Blood Donation
1628 British physician William Harvey discovers the circulation of blood. The first known blood transfusion is attempted soon afterward.
[141]
[PDF] Blood Program in World War II. Medical Department, United States ...
May 7, 2025 · The volumes comprising the official history of the Medical Department of the U.S. Army in World War II are prepared by The Historical Unit, ...
[142]
The History of Fluid Resuscitation for Bleeding - PMC
In 1915, Richard Lewisohn uses sodium citrate as an anticoagulant to transform the transfusion procedure from direct to indirect with the capability of storage.
[143]
The thin red line: Blood planning factors and the enduring... - LWW
Jul 12, 2024 · Mortality rates from combat injuries have decreased since the beginning of the 20th century with the introduction of blood transfusion in World ...Missing: empirical | Show results with:empirical
[144]
A Brief History of Blood Transfusion Through The Years
Mar 10, 2016 · 1818 James Blundell performs the first successful blood transfusion of human blood to treat postpartum hemorrhage. 1840 The first whole blood ...<|separator|>
[145]
Acid-Citrate-Dextrose - an overview | ScienceDirect Topics
CPD, with a 3-week shelf life, became the standard whole blood storage solution used in the United States from 1957 to 1979. Blood Bags and the Onset of ...
[146]
Introduction - HIV And The Blood Supply - NCBI Bookshelf
In the early 1980s, blood became a vector for HIV infection and transmitted a fatal illness to approximately half of the 16,000 hemophiliacs in the United ...
[147]
History and Future of Nucleic Acid Amplification Technology Blood ...
Feb 5, 2019 · The history of blood donation NAT dates back to the late 1980s, when PCR was used to identify post-transfusion HCV and HIV-1 transmission rates ...
[148]
[PDF] Transfusion-associated adverse events and implementation of blood ...
Feb 26, 2021 · Rates of TTIs reported in. 2017 were 0.23 (95% CI, 0.13–0.34), 0.039 (95% CI, 0–0.090) and 0.068 (95% CI, 0.010–. 0.125) reactions per 100,000 ...Missing: modern | Show results with:modern
[149]
Standards for Blood Banks and Transfusion Services - AABB
AABB sets standards for blood banks and transfusion services, designed to ensure the highest levels of quality and safety for patients and donors at all times.
[150]
[PDF] Requirements for Blood and Blood Components Intended for ... - FDA
In addition, according to current AABB standards, blood banks and transfusion services should have methods (1) to limit, and (2) to detect or inactivate.
[151]
Trends in blood transfusion and causes of blood wastage
Jan 14, 2025 · During this period, transfusion reaction rates decreased markedly, from 1.8% in 2011 to 0.6% in 2023. The decline became more pronounced after ...
[152]
Incidence of acute transfusion reactions and associated... - LWW
Aug 9, 2024 · The severity of the reaction and the degree of morbidity are usually related to the degree of ABO incompatibility and the volume of blood ...
[153]
Pathogen-reduction technology, good in more than one way for ...
Feb 4, 2025 · PRT would then enable leukocyte inactivation for 100 % of the blood supply, beneficial for transfusion safety in all patients. Keywords: HLA; ...Missing: genotyping 2020s
[154]
[PDF] T-1 Department of Veterans Affairs VHA DIRECTIVE 1106 Veterans ...
Jan 24, 2024 · NOTE: Patient blood management is a program that encompasses all aspects of patient evaluation and clinical management surrounding the ...
[155]
Retooling the Massive Transfusion Protocol at a Veterans Affairs ...
Massive transfusion protocols (MTPs) ensure the timely and life-saving delivery of blood products to patients who are rapidly exsanguinating. Although essential ...
[156]
Neonatal and pediatric transfusion | Professional Education
Aug 2, 2017 · The use of CMV-seronegative blood products for transfusion in low birth weight neonates is not deemed necessary. The primary rationale is that ...
[157]
[PDF] PEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE ...
May 15, 2016 · • Typical circulating blood volume for term infants is 80-90 ml/kg. Typical circulating blood volume for preterm infants is 90-100 ml/kg. VI ...
[158]
Calculating the required transfusion volume in children - PubMed
The following equation should be used to calculate transfusion volumes: weight (kg) x increment in Hb (g/dL) x 3/(hematocrit [Hct] level of RBCs).
[159]
Clinical Practice Guidelines : Blood product prescription
Transfusion volumes in non‐bleeding infants and children ; Red cells. <20 kg: Calculate using formula: mL = wt (kg) x 0.5 x Hb (g/L) rise (desired Hb – actual Hb)
[160]
[PDF] Guidelines for Transfusion of Pediatric Patients - Wadsworth Center
1. RBCs should be hemoglobin S negative, leukoreduced, < 7 days old, and CMV reduced risk. Irradiation is essential if the infant has undergone intrauterine ...<|separator|>
[161]
Prevention of Transfusion-Associated Graft-Versus-Host Disease ...
May 1, 2018 · Preterm neonates (<4 months) are at risk for TA-GVHD, and the risk increases significantly if the newborn had received prior intrauterine ...
[162]
Transfusion Associated Graft Versus Host Disease - an overview
Irradiation of blood components at 25 Gy prevents TA-GVHD by eliminating the donor lymphocyte mitogenic response. All cellular blood components should be ...
[163]
Transfusion practice in neonates - PMC - NIH
Transfusion of CMV-seronegative blood is considered necessary to preventing TT-CMV infections, but such products are difficult to obtain due to the high ...
[164]
Irradiated, washed and CMV seronegative blood components
Mar 2, 2021 · This chapter describes the preparation of irradiated, washed, and CMV seronegative cellular blood components (red blood cells and platelets)
[165]
Higher or Lower Hemoglobin Transfusion Thresholds for Preterm ...
Dec 30, 2020 · In our trial, a higher hemoglobin threshold for transfusion was associated with an increase in the number of transfusions administered. However, ...
[166]
Effects of Liberal vs Restrictive Transfusion Thresholds on Survival ...
Aug 11, 2020 · This randomized clinical trial assesses the effect of liberal vs restrictive red blood cell transfusion thresholds (based on postnatal age ...
[167]
Clinical Practice Guideline for Transfusion Thresholds in Preterm ...
Jun 14, 2024 · This consensus statement recommends a restrictive RBC transfusion strategy, with moderate certainty of evidence, for preterm neonates with less than 30 weeks' ...
[168]
Hemoglobin Threshold for Blood Transfusion in a Pediatric Intensive ...
The hemoglobin threshold for transfusion varied according to clinical conditions. Overall, the hemoglobin threshold for transfusion was 7.3 ± 1.20 g/dl.
[169]
Transfusions in Pediatrics | American Academy of Pediatrics
Sep 1, 2025 · Irradiation is recommended for neonates, patients receiving a transfusion from an HLA antigen-compatible or blood-related donor, patients with a ...<|control11|><|separator|>
[170]
Permissive Hypotension vs. Conventional Resuscitation in Patients ...
Jul 19, 2021 · Permissive hypotension limits blood loss while maintaining adequate perfusion and positively impacts outcomes in actively hemorrhaging trauma ...
[171]
Permissive hypotension • LITFL • CCC Resuscitation
Permissive hypotension is also known as hypotensive resuscitation and low volume resuscitation. Injection of a fluid that will increase blood pressure has ...
[172]
Permissive Hypotension for Trauma Patients with Hemorrhagic Shock
Jan 3, 2019 · In meta-analysis, permissive hypotension resulted in a relative risk of 0.50 for mortality and lower rates of organ dysfunction and acute ...
[173]
Controlled Resuscitation in Trauma Patients Clinical Practice ...
Permissive hypotension is not recommended for patients with a suspected traumatic brain injury (maintain SBP>90mmHg) as this could contribute to poor outcomes.
[174]
Fluids in traumatic haemorrhage - PMC - NIH
Large volumes of crystalloids used to replace blood loss have a detrimental effect on outcomes and can cause a dilutional coagulopathy, alongside an acute ...Fluids In Traumatic... · Crystalloids · Blood Products
[175]
Trauma-induced coagulopathy | Nature Reviews Disease Primers
Apr 29, 2021 · Thrombin generation can be altered by dilution of coagulation factors following fluid therapy, rapid coagulation factor consumption ...
[176]
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1 ... - NIH
Blood product ratios were calculated as 2 separate ratios: plasma to RBCs and platelets to RBCs. For example, a 1:1 ratio of plasma to RBCs is equivalent to 1.0 ...
[177]
Volume replacement in the resuscitation of trauma patients with ...
Nov 30, 2023 · However, the administration of blood products compared to crystalloids may avoid a dilution of coagulation factors, leading to a higher ...Comparison 2: Blood... · 2b. Blood Components Ratios · Author Information
[178]
Prehospital Tranexamic Acid for Severe Trauma
Jun 14, 2023 · Tranexamic acid, administered within 3 hours after injury, was shown to reduce 28-day mortality among patients with suspected bleeding (CRASH-2 ...
[179]
Damage Control Resuscitation - PMC - PubMed Central
Tranexamic acid should be routinely used in trauma patients with evidence of bleeding. Tranexamic acid should be included in transfusion protocols for trauma.
[180]
Timing to First Whole Blood Transfusion and Survival Following ...
Jan 31, 2024 · Less time to first whole blood transfusion was associated with a reduced time to death at 24 hours and 30 days, with a survival benefit seen as early as 1 hour ...
[181]
Prehospital Blood Transfusion | EMS.gov
Sep 4, 2025 · Improved patient outcomes – Trauma patients who received whole blood in the field were four times more likely to survive than those who did not.
[182]
Preferential whole blood transfusion during the early resuscitation ...
Apr 22, 2024 · Preferential whole blood transfusion during the early resuscitation period is associated with decreased mortality and transfusion requirements ...
[183]
[PDF] Guidelines for Use of Group O Rh Negative RBCs - Versiti
For emergency-release uncrossmatched RBCs (e.g. 1-2 units; massive transfusion not activated) when blood type is unknown. Limit to no more than 2 units. Switch ...
[184]
Emergency transfusion of patients with unknown blood ... - PubMed
Here we report the outcome of this transfusion policy transfusing all emergency patients with unknown blood type with O RhD+ red blood cell concentrates.
[185]
Blood Safety and Matching - American Society of Hematology
... Type A, Type B, Type AB, or Type O blood. In emergency situations, when the recipient's blood type is unknown, the person can receive type O negative red ...Missing: protocol | Show results with:protocol
[186]
[PDF] Preparatory Actions Emergency Transfusion Actions
Start adult males and females past childbearing age on O positive red cells when blood type is unknown. Reserve O negative red cells for O negative.<|separator|>
[187]
[PDF] LS-POLICY-5053-Switching-from-O-Negative-Red-Blood-Cells-to-O ...
o Emergency room patient with unknown blood type: 3-6%. • Risk of acute hemolytic transfusion reaction after RhD-incompatible RBC transfusion during an.
[188]
[PDF] Low Titer Group O Whole Blood - Implications for Practice - Versiti
LTOWB is quite low. Group O. RBCs in LTOWB are considered the universal donor and can safely be given to anyone, even those of unknown blood type. The plasma.
[189]
the modern renaissance of low titer group O whole blood for treating ...
According to the AABB Standards, when used in an uncrossmatched manner, the whole blood must be group O and contain low titer anti-A and -B; this product is ...The rationale for intervening... · Whole blood collection... · Is transfusing LTOWB...
[190]
low-titer group O whole blood resulted in less total transfusions and ...
Low-titer group O whole blood (LTOWB) or component therapy (CT) may be used to resuscitate hemorrhaging trauma patients. LTOWB may have clinical and logistical ...
[191]
Diagnostic Accuracy of a Point-of-Care Blood Typing Kit Conducted ...
ABSTRACT. The usability of a rapid point-of-care ABO-Rh blood typing kit was determined by comparing the performance of individuals with extensive medical.
[192]
A Micro-Lab on a Chip Detects Blood Type within Minutes
A lab-on-a-chip device that can not only tell the blood type within five minutes but allows medical staff to read the results through simple visual inspections.
[193]
Rh Blood Group D Antigen Genotyping Using a Portable Nanopore ...
Sep 1, 2022 · The study used a portable nanopore device to sequence the RHD gene, achieving high coverage and enabling confident variant calling for Rh blood ...
[194]
Rapid and Cost-Effective ABO Blood Genotyping Using a Freeze ...
To enhance usability for point-of-care applications, freeze-dried reagents were developed that permit direct loading of lysed blood samples while maintaining ...
[195]
Why Don't Jehovah's Witnesses Accept Blood Transfusions?
This is a religious issue rather than a medical one. Both the Old and New Testaments clearly command us to abstain from blood.What Does the Bible Say... · Do Jehovah’s Witnesses... · Leviticus 17 | Online Bible
[196]
What Does the Bible Say About Blood Transfusions? - JW.ORG
The Bible commands that we not ingest blood. So we should not accept whole blood or its primary components in any form, whether offered as food or as a ...
[197]
How Do I View Blood Fractions and Medical Procedures Involving ...
The Bible commands Christians to “abstain from . . . blood.” (Acts 15:20) Thus, Jehovah's Witnesses do not accept transfusions of whole blood or the four ...Missing: doctrine | Show results with:doctrine
[198]
Outcome of Patients Who Refuse Transfusion After Cardiac Surgery
Jul 2, 2012 · Results Witnesses had fewer acute complications and shorter length of stay than matched patients who received transfusions: myocardial ...
[199]
Methods of Bloodless Care, Clinical Outcomes, and Costs for Adult ...
Sep 1, 2022 · Conclusions: Overall, adult patients receiving bloodless care had similar clinical outcomes compared to patients receiving standard care.
[200]
Outcomes of cardiac surgery in Jehovah's Witness patients: A review
The use of a bloodless protocol for Jehovah's Witnesses does not appear to significantly impact upon clinical outcomes when compared to non-Witness patients.
[201]
In Re EG :: 1989 :: Supreme Court of Illinois Decisions - Justia Law
This court has also held that an adult may refuse life-saving blood transfusions on first amendment free exercise of religion grounds. (In re Estate of Brooks ( ...
[202]
Adults who refuse blood transfusion in emergency, urgent and ... - NIH
However, powerful evidence will be required to persuade the court that a patient's competent wish to refuse blood can be overruled and this is unlikely to ...
[203]
A Patient's Right to Refuse Medical Treatment
Competent patients have the right to refuse any medical treatment, including blood and blood product transfusions, for themselves.6 Accordingly, a competent ...
[204]
AABB recommends restrictive RBC transfusions for hospitalized ...
Feb 6, 2024 · For hospitalized adults and children, AABB generally recommends restrictive RBC strategies, with a transfusion threshold hemoglobin level of 7 g/dL.
[205]
Expert Panel Recommends Liberal Transfusion Strategy for ... - AABB
Aug 20, 2025 · An international panel of experts convened by AABB recommended a liberal red blood cell (RBC) transfusion strategy for hospitalized patients ...
[206]
Liberal versus restrictive red blood cell transfusion strategy in acute ...
Apr 23, 2025 · Our meta-analysis demonstrated that a liberal RBC transfusion strategy reduced the risk of MI and increased the risk of acute lung injury.Abstract · Methods · Results · Discussion
[207]
Counterpoint: the design and interpretation of blood transfusion ...
Aug 7, 2025 · FOCUS trial. The FOCUS trial randomly ... , et al. A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery.
[208]
MINT – Restrictive or Liberal Transfusion Strategy in Myocardial ...
May 23, 2025 · There exists a large body of well conducted randomised controlled trials generally supporting the safety of a restrictive transfusion strategy in critically ...
[209]
Effect of liberal blood transfusion on clinical outcomes and cost in ...
Apr 27, 2017 · Transfusion using a liberal trigger is associated with increased morbidity, even after controlling for possible confounders.
[210]
Do liberal blood transfusions cause more harm than good? - The BMJ
Jan 3, 2015 · A unit of red blood cells costs £121 in England, and there are the further costs of laboratory testing, storage of blood, administer- ing blood, ...
[211]
Blood Product Overtransfusion Is a Global Issue: Here Are 5 ...
Oct 9, 2024 · Overtransfusion causes multiple adverse outcomes, including increased mortality, immune suppression, respiratory failure, kidney failure, extended hospital and ...Missing: trials | Show results with:trials
[212]
Blood transfusion trends in the United States: national inpatient ...
There is significant decline in RBC and plasma transfusions nationally among hospitalized patients in the United States through 2018.
[213]
Blood transfusion trends by disease category in the United States ...
Blood transfusion rates decreased from 2011 to 2014 in the United States. This decline occurred in most disease categories, which points towards broad ...
[214]
Hemoglobin-based transfusion strategies for cardiovascular and ...
Nov 14, 2024 · A “restrictive” red blood cell transfusion threshold, a hemoglobin concentration <7 to 8 g/dL, has long been recommended for most hospitalized patients.Anemia, CVD, and transfusion · Transfusion strategies for other... · path forward
[215]
Plasma donations: A financial lifesaver and an ethical dilemma
Mar 6, 2024 · Plasma pay can reach as high as $200 per donation during times of severe shortages, and advertisements pitch earnings of $800 per month for new donors.
[216]
Plasma Donors Are Being Exploited in America - Jacobin
Aug 23, 2023 · The United States is one of five countries where it's legal to sell your plasma, and roughly 20 million people here do it every year.
[217]
Blood Donation, Payment, and Non-Cash Incentives - PubMed Central
Several recent studies have shown that altruism, even if present as a motivation, is not strongly related to actual donation behaviour [52, 59, 64]. Other ...
[218]
Blood safety and availability - World Health Organization (WHO)
May 30, 2025 · An adequate and reliable supply of safe blood can be assured by a stable base of regular, voluntary, unpaid blood donors. These donors are also ...Missing: equivalence | Show results with:equivalence
[219]
Selling plasma helps pay the bills but raises ethical concerns ...
Jun 8, 2024 · U.S. regulatory limits allow donors to give plasma up to twice a week or 104 times a year while many other countries have stricter limits on ...
[220]
Important Information About Directed Blood Donations that are ... - FDA
Oct 23, 2023 · Studies suggest that directed donations may carry greater risk of transmitting infectious diseases than the general blood supply. In addition, ...
[221]
Blood Community Experts Warn Against Non–Medically Indicated ...
Jun 12, 2025 · They emphasized that directed donations are not safer than the community blood supply, may delay transfusion in emergency situations, and could ...
[222]
Autologous and Directed Donations - Red Cross Blood Donation
Social pressure associated with directed donations may compromise the reliability of the donor's answers to health-history questions.
[223]
Unvaccinated donor blood requests present serious safety issues
Jun 11, 2025 · First, directed donors are often first-time or infrequent donors. Because of this, they are more likely to pose risks to blood safety. Large ...
[224]
Post-COVID-19 Blood Supply… | College of American Pathologists
Post-COVID-19 Blood Supply Challenges: Requests for Blood from Unvaccinated Donors · Blood centers do not defer donors based on vaccination status. · Vaccine ...Missing: debates | Show results with:debates
[225]
Duration of SARS-CoV-2 mRNA vaccine persistence and factors ...
Sep 27, 2023 · These results suggest that SARS-CoV-2 mRNA vaccines routinely persist up to 30 days from vaccination and can be detected in the heart.<|separator|>
[226]
Medical, Societal, and Ethical Considerations for Directed Blood ...
May 13, 2025 · Requests for "nonvaccinated" blood, driven by misconceptions about vaccine safety, have led to legislative attempts to mandate compliance.Missing: unvaccinated debates
[227]
Refusing blood transfusions from COVID‐19‐vaccinated donors
Sep 15, 2021 · Despite the variation in deferral policies, there is no evidence that blood donations from COVID-19-vaccinated donors pose any risk to ...
[228]
Payment for plasma raises ethical issues - PMC - NIH
An Ontario-based company is now compensating donors for plasma, giving rise to a divide in the medical community about the safety and ethics of paying for ...
[229]
Jehovah's Witnesses and artificial blood - PMC - NIH
Although it is well known that orthodox Jehovah's Witnesses may not accept blood transfusions, even when medically necessary to save life.
[230]
Ethical and legal aspects of refusal of blood transfusions by ... - NIH
The patient, for his/her part, has the right to refuse blood transfusions on religious grounds (autonomy) provided he or she is competent and able to do so.
[231]
[PDF] Judicial Intrusion Upon the Practices of Jehovah's Witness Parents
Members of the Jehovah's Witness faith have endured numerous intrusions by the Florida judicial system in their struggle to refuse blood transfusions on ...
[232]
Pediatric and Adolescent Jehovah's Witnesses: Considerations for ...
Courts have consistently deemed that the state can intervene to protect children and that parents “do not have an absolute right” to medical treatment refusal.
[233]
[PDF] Informed Consent for Blood Transfusion - AABB
Feb 23, 2023 · Although it could be argued from an ethical standpoint that such risks should be disclosed, the intent of the informed consent process is to ...
[234]
Risk-adjusted clinical outcomes in patients enrolled in a bloodless ...
Jun 18, 2014 · Overall, mortality was lower in the bloodless group (0.7%) than in the control group (2.7%; p = 0.046), primarily attributed to the surgical ...Missing: empirical | Show results with:empirical
[235]
Patient Blood Management - UF Health
Jul 14, 2025 · Bloodless medicine is a special way of treating you without transfusing blood. ... Hemopure is an artificial blood substitute made from cow blood ...Benefits To The Patient · Anemia Screening · Hear About Pbm From Our Team
[236]
Multimodal Patient Blood Management Program Based on a... - LWW
A comprehensive PBM program addressing all 3 PBM pillars is associated with reduced transfusion need of red blood cell units, lower complication and mortality ...
[237]
The pillars of patient blood management: key to successful ...
Sep 4, 2019 · After PBM implementation, they showed significant reductions in RBC and platelet transfusions, accompanied by decreased transfusion-related ...
[238]
Penny-wise and pound-foolish: the challenges of preoperative ...
According to a 2021 systematic review, intravenous iron repletion before major surgery was associated with a 16% reduction in the proportion of patients ...Centenary Editorial · Efficacy Of Anaemia... · Cost Savings Associated With...<|separator|>
[239]
Preoperative erythropoietin within a patient blood management ...
Within a PBM, preoperative treatment of anemia with EPO decreased both the rate of blood transfusion and postoperative anemia.
[240]
Perioperative blood management: Strategies to minimize transfusions
Aug 12, 2025 · Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.
[241]
Cell salvage as part of a blood conservation strategy in anaesthesia
Cell salvage has been demonstrated to be safe and effective at reducing allogeneic blood transfusion requirements in adult elective surgery.
[242]
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes ...
Conclusions— All antifibrinolytic agents were effective in reducing blood loss and transfusion. There were no significant risks or benefits for mortality, ...
[243]
Restrictive or Liberal Transfusion Strategy in Myocardial Infarction ...
Nov 11, 2023 · A strategy of administering a transfusion only when the hemoglobin level falls below 7 or 8 g per deciliter has been widely adopted.
[244]
Restrictive vs Liberal Transfusion Strategy in Patients With Acute ...
Oct 9, 2024 · A liberal transfusion strategy compared with a restrictive strategy resulted in a lower rate of unfavorable neurological outcome among patients with acute ...
[245]
Guidance on implementing patient blood management to improve ...
Apr 23, 2025 · This guidance shows how the necessary structures and processes can be broadly replicated to improve overall population health.Missing: settings | Show results with:settings
[246]
Patient blood management data and metrics—two key components
Sep 30, 2025 · PBM's three pillars are: optimization of blood volume and red cell mass; minimization of blood loss; and optimization of the patient's tolerance ...
[247]
Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?
Feb 17, 2023 · Hemopure was evaluated in human cardiac trials, in which it showed increased coronary oxygenation and perfusion. Hemopure is unique because ...
[248]
HBOC-201: The multi-purpose oxygen therapeutic | EuroIntervention
A full toxicology profile was completed for HBOC-201, including general toxicity (acute and repeat dose), cardiotoxicity, genotoxicity, reproductive toxicity, ...Missing: approvals | Show results with:approvals
[249]
New Applications of HBOC-201: A 25-Year Review of the Literature
Dec 8, 2021 · Bovine hemoglobin in a dose range of 55–97 g hemoglobin increases vascular resistance and reduces cardiac output in patients undergoing ...
[250]
Hemoglobin-based Oxygen Carriers: Current Status and Future - LWW
In the prespecified ITT population, the mortality for the test group was 13% (47 of 350) and 10% (35 of 364) for the control group, failing the prespecified 7% ...
[251]
A Review of Blood Substitutes: Examining The History, Clinical Trial ...
47 The study found that patients treated with an HBOC had a 30% increased risk of mortality and a 2.7-fold increase for myocardial infarction. Further analyses ...
[252]
Hemoglobin-based oxygen carriers, oxidative stress and myocardial ...
Apr 14, 2025 · Such concerns were crystallized by a meta-analysis demonstrating increased risk of mortality and myocardial infarction (MI) after HBOC infusion ...
[253]
Perfluorocarbon-based oxygen carriers: What is new in 2024?
Albumin-derived perfluorocarbon-based artificial oxygen carriers are the newest development in PBOC field of blood substitute/oxygen therapeutics.
[254]
Perfluorocarbon-based artificial oxygen carriers for red blood cell ...
Feb 16, 2024 · The development of an artificial oxygen carrier that can replace blood transfusions is gaining attention, particularly in response to war and the COVID-19 ...
[255]
Banking on Artificial Blood | ASH Clinical News
Feb 20, 2025 · In more recent memory, potential blood substitutes have been divided into two categories: perfluorocarbons (PFCs) and hemoglobin-based oxygen ...
[256]
Hemoglobin‐based oxygen carriers: Biochemical, biophysical ...
Jan 2, 2025 · First‐generation products are referred to as HBOCs that have undergone clinical trials ... clinical trial data showing increased mortality ,.
[257]
the emerging potential of induced pluripotent stem cells (iPSCs) - NIH
Dec 26, 2024 · The focus has switched to the in vitro synthesis of red blood cells (RBCs) from induced pluripotent stem cells (iPSCs) as a potential solution.
[258]
Engineering Synthetic Erythrocytes as Next-Generation Blood ... - NIH
A landmark clinical trial – the first involving lab-grown erythrocytes – is currently ongoing and aims to evaluate the survival of these cells in humans.
[259]
Toward universal donor blood: Enzymatic conversion of A and B to ...
Jan 10, 2020 · Conversion of A, B, and AB RBCs to O-type RBCs should be achievable by removal of that sugar with an appropriate glycosidase.
[260]
Novel GH109 enzymes for bioconversion of group A red blood cells ...
Nov 25, 2023 · The specific GHs able to convert RBC of group A to group O, have been identified in the family GH109 of the Carbohydrate Active enZymes ...
[261]
Enzymatic Conversion of Red Blood Cell Antigens to the Universal ...
Mar 11, 2024 · The research uses exo-glycosidases to convert A and B antigens on red blood cells to the universal type O, using two enzyme cocktails.
[262]
ABO gene editing for the conversion of blood type A to universal ...
Oct 25, 2022 · In order to convert the Rhnull hiPSC line from blood type A to the universal type O, we designed two strategies based on CRISPR/Cas9 technology.
[263]
ABO gene editing for the conversion of blood type A to universal ...
Oct 25, 2022 · CRISPR/Cas9 mediated ABO gene edition allows the conversion of blood type A to universal type O in Rhnull donor-derived hiPSCs A targeted ...
[264]
CRISPR-Cas9-driven antigen conversion of clinically relevant blood ...
Apr 2, 2025 · Combining cRBCs with blood group gene editing could broaden transfusion accessibility by making antigen expression compatible with rare phenotypes.
[265]
Progress in Development of Functional Biological and Synthetic ...
Mar 4, 2025 · A major challenge facing RBC manufacturing as a viable clinical tool is improving scale-up RBC differentiation. RBC production is a balance ...
[266]
https://researchgate.net/publication/370264158_Generation_of_Rh_D-negative_blood_using_CRISPRCas9
[267]
There's a Shortage of Blood. So Why Don't We Make Some?
Nov 15, 2024 · A CU School of Medicine professor calls synthetic blood “one of the holy grails of biomedical research,” but creating an ample supply is still a long way off.Missing: erythrocytes | Show results with:erythrocytes
[268]
Transfusion Guidelines | Cornell University College of Veterinary ...
Transfusion Guidelines ; Fresh and fresh frozen plasma, 6 to 12 ml/kg, q. 8 to 12 h, coagulation factor deficiencies, vWD, DIC, hypoproteinemia ; Frozen plasma, 6 ...
[269]
Blood transfusion in veterinary medicine - MedCrave online
May 12, 2017 · Blood transfusions in veterinary medicine improve oxygen and treat anemia, but have risks. It is used in many clinics, and can be life-saving.
[270]
Transfusion Medicine in Small Animals - Veterinary Clinics
Red blood cell transfusions are the treatment of choice for anemia. Use of plasma is indicated for the treatment of active bleeding caused by coagulopathy.
[271]
Discovery of blood transfusion - Animal Research Info
Jun 13, 2023 · The earliest, well-authenticated account of the transfusion of blood from one dog to a second is that of Richard Lower, who in February 1665 ...
[272]
Richard Lower: the origins of blood transfusion - PubMed
This practice began in the 17(th) century with an English physician. In 1666, Richard Lower reported the first successful transfusion between animals.
[273]
Practical Veterinary Transfusion Medicine - WSAVA2005 - VIN
It is important that veterinarians use typed, compatible blood whenever a transfusion is given. For cats, cross-matching the recipient and donor beforehand is ...
[274]
Blood Transfusions in General Veterinary Practice - Dispomed
Jul 10, 2023 · Learn key protocols for blood transfusions in general veterinary practice—covering blood typing, cross‑matching, dosage calculation, ...
[275]
Transfusion therapy | eClinpath
As a general rule, whole blood transfusions should be limited to those animals requiring coagulation factors, platelets, and red cells. Whole blood should not ...<|separator|>
[276]
Blood Transfusion Reactions in Dogs | VCA Animal Hospitals
Examples include fluid overload (when the body is unable to tolerate the increased blood volume that results from a transfusion), citrate toxicity (an uncommon ...
[277]
Adverse reactions | eClinpath
The most common reactions to transfusions are fever, vomiting and facial edema. These are generally mild. More severe reactions, including intravascular ...
[278]
Association of Veterinary Hematology and Transfusion Medicine ...
Mar 31, 2021 · To use a systematic, evidence-based consensus process to develop definitions for transfusion reactions in dogs and cats.